



PROF. CHRISTOS ZOUBOULIS (Orcid ID : 0000-0003-1646-2608)

PROF. EVANGELOS JOHN GIAMARELLOS-BOURBOULIS (Orcid ID : 0000-0003-4713-3911)

DR. JOHN W FREW (Orcid ID : 0000-0001-5042-3632)

DR. MARCOS ANTONIO GONZÁLEZ-LÓPEZ (Orcid ID : 0000-0003-2423-5800)

DR. JOSE C. PASCUAL (Orcid ID : 0000-0001-8279-215X)

DR. JACEK C. SZEPIETOWSKI (Orcid ID : 0000-0003-0766-6342)

Article type : Review Article

### **What causes hidradenitis suppurativa ? – 15 years after**

Christos C. Zouboulis<sup>1,2</sup>, Farida Benhadou<sup>1,3</sup>, Angel S. Byrd<sup>4</sup>, Nisha S. Chandran<sup>1,5</sup>, Evangelos J. Giamarellos-Bourboulis<sup>1,6</sup>, Gabriella Fabbrocini<sup>1,7</sup>, John W. Frew<sup>8</sup>, Hideki Fujita<sup>9</sup>, Marcos A. González-López<sup>1,10</sup>, Philippe Guillem<sup>1,11</sup>, Wayne P. F. Gulliver<sup>1,12</sup>, Iltefat Hamzavi<sup>13</sup>, Yildiz Hayran<sup>14</sup>, Barbara Hórvath<sup>1,15</sup>, Sophie Hüe<sup>16</sup>, Robert E. Hunger<sup>1,17</sup>, John R. Ingram<sup>1,18</sup>, Gregor B.E. Jemec<sup>1,19</sup>, Qiang Ju<sup>1,20</sup>, Alexa B. Kimball<sup>21</sup>, Joslyn S. Kirby<sup>22</sup>, Maria P. Konstantinou<sup>23</sup>, Michelle A. Lowes<sup>8</sup>, Amanda S. MacLeod<sup>24</sup>, Antonio Martorell<sup>1,25</sup>, Angelo V. Marzano<sup>1,26,27</sup>, Łukasz Matusiak<sup>1,28</sup>, Aude Nassif<sup>1,29</sup>, Elena Nikiphorou<sup>30</sup>, Georgios Nikolakis<sup>1,2</sup>, André Nogueira da Costa<sup>1,31</sup>, Martin M. Okun<sup>32</sup>, Lauren A.V. Orenstein<sup>33</sup>, José Carlos Pascual<sup>1,34</sup>, Ralf Paus<sup>1,35</sup>, Benjamin Perin<sup>36</sup>, Errol P. Prens<sup>1,37</sup>, Till A. Röhn<sup>38</sup>, Andrea Szegedi<sup>39</sup>, Jacek C. Szepietowski<sup>1,28</sup>, Thrasyvoulos Tzellos<sup>1,40</sup>, Baoxi Wang<sup>1,41</sup>, Hessel H. van der Zee<sup>1,37</sup>

<sup>1</sup>European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany

<sup>2</sup>Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany

<sup>3</sup>Department of Dermatology, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium

<sup>4</sup>Department of Dermatology, Howard University College of Medicine, Washington, DC, USA

<sup>5</sup>Division of Dermatology, Department of Medicine, National University Hospital, Singapore

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/EXD.14214](https://doi.org/10.1111/EXD.14214)

This article is protected by copyright. All rights reserved

<sup>6</sup>4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Greece

<sup>7</sup>Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy

<sup>8</sup>The Rockefeller University, New York, NY, USA

<sup>9</sup>Division of Cutaneous Science, Department of Dermatology, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan

<sup>10</sup>Division of Dermatology, Hospital Universitario Marqués de Valdecilla, University of Cantabria, IDIVAL, Santander, Cantabria, Spain

<sup>11</sup>Department of Surgery, Clinique du Val d'Ouest (Lyon), ResoVerneuil ( Paris) and Groupe de Recherche en Proctologie de la Société Nationale Française de ColoProctologie, Paris, France

<sup>12</sup>Faculty of Medicine, Memorial University of Newfoundland, and NewLab Clinical Research Inc., St. John's, Canada

<sup>13</sup>Department of Dermatology, Henry Ford Hospital, Wayne State University, Detroit, MI, USA

<sup>14</sup>Department of Dermatology, Ankara Numune Training and Research Hospital, Ankara, Turkey

<sup>15</sup>Department of Dermatology University Medical Centre Groningen, University of Groningen, Groningen The Netherlands

<sup>16</sup>INSERM U955 team 16, Créteil, France

<sup>17</sup>Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland

<sup>18</sup>Department of Dermatology & Academic Wound Healing, Division of Infection and Immunity, Cardiff University, Cardiff, UK

<sup>19</sup>Department of Dermatology, Zealand University Hospital, Roskilde, Denmark

<sup>20</sup>Department of Dermatology, RenJi Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

<sup>21</sup>Department of Dermatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA

<sup>22</sup>Department of Dermatology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA

<sup>23</sup>Dermatology Department, Paul Sabatier University, University Hospital of Toulouse, Toulouse, France

<sup>24</sup>Department of Dermatology, Department of Immunology, Department of Molecular Genetics and Microbiology, Duke University, Durham, NC, USA

<sup>25</sup>Department of Dermatology, Hospital of Manises, Valencia, Spain

<sup>26</sup>Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

<sup>27</sup>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy

<sup>28</sup>Department of Dermatology, Venereology and Allergology, Wrocław Medical University, Wrocław, Poland

<sup>29</sup>Institut Pasteur, Paris, France

<sup>30</sup>Centre for Rheumatic Diseases, King's College London, and Department of Rheumatology, King's College Hospital, London, UK

<sup>31</sup>Translational Science and Experimental Medicine, Early Respiratory and Immunology, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

<sup>32</sup>Fort HealthCare, Fort Atkinson, WI, USA

<sup>33</sup>Department of Dermatology, Emory University School of Medicine, Atlanta, GA, USA

<sup>34</sup>Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), Spain

<sup>35</sup>Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA

<sup>36</sup>Division of Dermatology, University of Washington, Seattle, WA, USA

<sup>37</sup>Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands

<sup>38</sup>Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland

<sup>39</sup>Division of Dermatological Allergology, Department of Dermatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

<sup>40</sup>Department of Dermatology, Nordland Hospital Trust, Bodø, Norway

<sup>41</sup>Department of Dermatology, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

**Funding:** None

Word count: 6521

Number of references: 200

Tables: 1

Figures: 6

**Corresponding author:** Prof. Dr. Christos C. Zouboulis, Departments of Dermatology,  
Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical  
School Theodor Fontane, Dessau, Germany, Auenweg 38, 06847 Dessau, Germany  
Tel: +49 340 5014000 – Fax: +49 340 5014025  
E-mail: [christos.zouboulis@mhb-fontane.de](mailto:christos.zouboulis@mhb-fontane.de)

## **ABSTRACT**

The 14 authors of the first review article on hidradenitis suppurativa (HS) pathogenesis published 2008 in EXPERIMENTAL DERMATOLOGY cumulating from the 1<sup>st</sup> International Hidradenitis Suppurativa Research Symposium held March 30–April 2, 2006 in Dessau, Germany with 33 participants were prophetic when they wrote “Hopefully, this heralds a welcome new tradition: to get to the molecular heart of HS pathogenesis, which can only be achieved by a renaissance of solid basic HS research, as the key to developing more effective HS therapy.” (Kurzen et al. What causes hidradenitis suppurativa?. *Exp Dermatol* 2008;17:455). Fifteen years later, there is no doubt that the wished renaissance of solid basic HS research is ongoing with rapid steps and that HS has developed deep roots among inflammatory diseases in Dermatology and beyond, recognized as “the only inflammatory skin disease than can be healed”. This anniversary article of 43 research-performing authors from all around the globe in the official journal of the European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) and the Hidradenitis Suppurativa Foundation, Inc. (HSF USA) summarizes the evidence of the intense HS clinical and experimental research during the last 15 years in all aspects of the disease and provides information of the developments to come in the near future.

**Key words:** Hidradenitis suppurativa, Pathogenesis, Hair follicle, Inflammatory skin diseases

## **2005-2020: 15 YEARS OF CONTINUOUS LEARNING – WHAT HAS CHANGED IN OUR UNDERSTANDING OF DISEASE PATHOGENESIS IN-THE-BETWEEN?**

(G.B.E. Jemec, M.M. Okun)

Substantial advances have been made in our understanding of hidradenitis suppurativa/acne inversa (HS) since the previous review on “What causes hidradenitis suppurativa?” in this journal [1] and many new researchers have entered the field. In consequence the number of publications is growing exponentially. A global appreciation of the symptomatic impact of HS has emerged [2], along with a quantitative understanding of the associated systemic comorbidities [3]. The dysregulated gene pathways in lesional HS skin have been mapped [4], and genetic [5] and microbiome [6] contributions to disease pathogenesis have been explored. Much work remains to be done, but convincing evidence that pro-inflammatory cytokines play a central role [7], i.e. opening the possibility of targeted treatment, has led to clinical trials [8] and regulatory approval of adalimumab for treatment of HS. In turn, this has spurred a flurry of new trials with different drugs [9]. Trials need endpoints, and with fortuitous premonition a structured search for evidence-based outcome variables has been performed by the European Hidradenitis Suppurativa Foundation (EHSF) e.V. [10] and is also on its way led by the HISTORIC group [11]. Many other efforts are underway to understand HS and optimize the management of this hitherto secret scourge. Expect the future to bring much good for the many HS patients.

## **INFECTION, AUTOIMMUNITY OR BOTH?**

(A.V. Marzano, E. Nikiphorou)

The role of bacterial infections per se as the primary cause of HS has attracted a lot of controversy evolving knowledge as to the underlying pathogenesis. A wide range of bacteria, including *Staphylococcus aureus*, coagulase-negative staphylococci, *Corynebacterium* species and anaerobic agents, such as *Porphyromonas*, *Prevotella* and *Fusobacterium*, have been isolated from deep HS lesions [12,13]. Indeed, bacteria may act in HS as pathogen-associated molecular triggers of inflammation by creating patterns linking their receptors, including the transmembrane toll-like receptors and intracellular Nucleotide binding Oligomerization Domain (NOD)-like receptors [14]. A downregulation of the alarmins/antimicrobial peptides S100A7 and S100A9 [15] as well as an increased expression of antimicrobial cathelicidine LL-37 [16] have been detected in HS lesional skin, suggesting an innate immunity dysfunction leading to an altered host-microbiome crosstalk. Reports on the coexistence of HS with autoimmune diseases, such as systemic lupus erythematosus,

and autoinflammatory conditions, such as Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis (SAPHO) syndrome [17], support the role of autoimmunity/autoinflammation in HS pathogenesis. Interleukin (IL)-1 $\beta$  is a highly prominent cytokine in lesional skin of both classic HS [18] and Pyoderma gangrenosum, Acne, Suppurative Hidradenitis (PASH) syndrome, the main syndromic form of HS [19,20]. This cytokine plays a crucial role in autoinflammation [21], suggesting that there is an important autoinflammatory component in the HS pathogenesis [22]. This view is further supported by genetic mutations which are shared between HS and classic autoinflammatory diseases [20,21]. The latter encompass a huge spectrum of conditions characterized by episodes of neutrophil-driven, sterile inflammation in the affected organs, including the skin [212].

As a consequence of these mutations, the inflammasome, which is a protein complex in neutrophils and macrophages, activates the autoinflammatory process through an uncontrolled release of several pro-inflammatory cytokines such as IL-1, IL-17, IL-23 and Tumor Necrosis Factor (TNF)- $\alpha$ , all overexpressed in HS lesional skin [18,23]. With several new gene mutations coming into play, such as those involved in the  $\gamma$ -secretase complex [24] and in the keratinization pathway [25] on the background of alterations in the skin microbiome, HS can be regarded as a multifactorial, polygenic, autoinflammatory disease (Fig. 1).

## MUTATIONS AND HS: WHAT IS VALID?

(E. Prens, B. Wang)

Mutations of  $\gamma$ -secretase complex (GSC) genes *PSENEN*, *PSENI*, and *NCSTN* were first described in familial HS 10 years ago [26]. Mutations have since been reported in at least 41 patients or families world-wide, including 16 Chinese [27], 4 Japanese [28], 4 Jewish Ashkenazi [29], 3 French [30], 2 British [31], 2 Indian [32], 1 African American [33], 1 American (Caucasian) [34], 1 German [35] and 1 Dutch [36] kindreds, 4 sporadic cases (2 British, 1 Afro-Caribbean, and 1 American) [34,37], and 2 patients with unknown familial history. The reported 41 mutations of GSC genes include 28 in *NCSTN*, 12 in *PSENEN*, and one in *PSENI*, of which 12 are frameshifts, 11 result in nonsense mutations, 9 in missense mutations, and 9 are splice site mutations. GSC is an intramembrane protease complex able to cleave more than 90 transmembrane proteins. Mutations in GSC could affect activation of presenilin, prevent substrate binding and hinder intramembrane cleavage of select proteins. Most of the *PSENEN* gene mutations are associated with the “clinical subphenotype” of Dowling-Degos disease [5]. In HS patients with *NCSTN*

mutations, remarkable findings are the male predominance (1.7:1 vs 1:3 in regular HS) and the characteristic phenotype. Overall, GSC gene mutations occur only in around 6% of non-familial HS. Several other mutations have been associated with (syndromic) HS including *MEFV*, *POFUT1*, *PSTPIP1* and *FGFR2*. An intriguing question is what the functional consequences are of all these mutations and their causality. The GSC mutations were initially linked to decreased Notch signaling. Loss-of-function mutations would result in abnormal follicular differentiation, keratinization, occlusion, and cyst formation. However, no significant differential expression of Notch 1–4 was identified in HS lesional skin as well as other inflammatory dermatoses including psoriasis, alopecia areata and atopic dermatitis [38]. GSC-related proteases ADAM10 and ADAM17, seem more likely candidates. ADAM17, is associated with inflammatory bowel disease and involved in epidermal, ductal and hair follicle formation, and production of matrix metalloproteinases. Furthermore, Nicastrin mutations interact with ADAM17 activity. Functional studies comprising GSC substrates other than Notch, including epigenetic, environmental and metabolic factors should be considered. Other genetic approaches in regular non-familial HS, such as GWAS or exome-sequencing are highly needed to discover new inflammatory pathways that may lead to novel therapeutic targets for this debilitating condition.

One large scale study using one Greek cohort and another German cohort identified that carriers of more than six copy numbers of the  $\beta$ -defensin (hbD2) gene cluster of chromosome band 8p.23.1 had greater risk for the acquisition of HS (odds ratio 6.72). Carriage of more than six copy numbers was associated with less severe disease phenotype regarding the degree of purulence and the number of affected body areas. These patients were prone to high production of hbD2 from whole blood upon stimulation with *Staphylococcus aureus* [39].

## **SKIN TRANSCRIPTOME IN HS**

(B. Hórvath, A.S. MacLeod, A. Nogueira da Costa)

HS personalized medicine relies on understanding the molecular taxonomy and heterogeneity amongst HS patients. With the fast-evolving HS therapeutic landscape, defining the right drug for the right patient at the right time is critical. Currently, only adalimumab, a TNF- $\alpha$  inhibitor, is approved for treatment of HS moderate-severe disease, but interest exists for targeting additional immune factors.

Great strides have been achieved through HS skin transcriptomic studies initiating an in-depth investigation of the molecular events of HS disease [4,40-43]. The analysis of the HS



transcriptome has provided unforeseen signatures of inflammatory, epithelial, hair follicle, and sweat gland signaling molecules: Early innate immune responses including the upregulation of the alarmins S100A7, S100A7A, and S100A8/A9; downregulation of the eccrine sweat gland-specific antimicrobial peptide dermcidin and induction of proinflammatory cytokines IL-1, IL-17, TNF- $\alpha$  and interferons (Fig. 2). Aberrant adaptive immunity with marked increase in T and B cells and plasma cell signatures in HS could point to autoimmune causes or simply reflect the result of chronic inflammation in late-stage HS. Importantly, most of the previous transcriptomic studies were small and focused on moderate-severe HS limiting identification of potential HS disease drivers through early innate immune disease-associated molecules.

Large cohort transcriptomic studies including early and minimal HS disease in addition to moderate and severe cases and skin sample collection from lesional and anatomical site-matched non-lesional skin are required to identify reliable and potentially predictive biomarkers (Fig. 2). Beyond microarray and whole-genome RNA sequencing, novel single cell sequencing and spatial resolution approaches are pivotal to the understanding of HS heterogeneity and immunobiology aiming at defining specific endotypes. This will ultimately herald the development of personalized treatment approaches (Fig. 2). Such approaches are currently pursued through collaborative initiatives in other diseases and have shown success [44-46].

## **RACIAL BACKGROUND AND HS**

(H. Fujita, I. Hamzavi, L.A.V. Orenstein)

The role of race in HS pathogenesis is poorly understood. Observed differences in HS prevalence across epidemiologic studies are probably better explained by disparate study methodologies than by true geographic and demographic differences. In the United States, those of African American and biracial ancestry are disproportionately affected by HS [47], and this difference is even greater among adolescents [48]. In Brazil, Amerindians are less likely to develop HS compared to other racial groups [49].

Several studies have highlighted racial differences in the clinical characteristics of HS. In western Europe and America, HS is more common in women compared to men. However, studies from eastern nations including Singapore, South Korea, Malaysia and Japan [50-53] Turkey [54], Malta [55] and Tunisia [56] have observed higher prevalence in men. This male preponderance may be partially confounded by the relatively higher frequency of smoking among Asian men compared to women [50]. Gluteal distribution has been observed more frequently in Asian than in European

and American HS cohorts, possibly related to male predominance in the Asian cohorts [50]. Data regarding HS severity by race conflict, with one study suggesting that African American patients may have earlier disease onset and are more likely to present with advanced disease compared to Whites [57,58].

Genetic studies have identified several  $\gamma$ -secretase mutations linked to HS pathogenesis.

Although these mutations were initially reported in Han Chinese families, the same mutations have subsequently been detected in HS patients worldwide [59]. It is unknown whether the prevalence of these mutations differs by race [39], however known  $\gamma$ -secretase mutations explain the minority of familial HS cases [5].

Much remains to be learned about the influence of race on the pathogenesis of HS. Unfortunately, the vast majority of HS studies have failed to report participants' race or ethnicity [60]. Adequate representation of diverse patients across all demographic groups including race and ethnicity is critical to enhancing our understanding of disease pathogenesis and ensuring that treatments can meet the needs of all subgroups affected by this debilitating disease.

#### **DO PHENOTYPES INDICATE GENOTYPES?**

(J.R. Ingram, A. Martorell, H.H. van der Zee)

The clinical presentation of HS, regardless of severity, is undeniably heterogeneous. For instance, some patients form many cysts, lesions at ectopic locations, other form mainly perianal heavily inflamed deep tunnels or superficial plaques on the body, while others form mainly superficial lesions resulting in ice-pick like scarring. Because of this variety in presentation, different phenotypes are very likely to exist. Identifying these phenotypes could be of clinical relevance since different phenotypes could have variable prognosis and require different treatment strategies.

One example based on geography is that Asian HS patients are more likely to be male and have gluteal disease [61]. Whether this relates to differences in genotype, for example mutations in gamma secretase, remains to be investigated.

In 2013, Canoui-Poitrine et al were the first to propose three phenotypes [62]. However, it received little attention for a long period of time. Currently, the age of biologic HS treatment is fueling HS research and phenotypes are more relevant than ever. More recently, Martorell et al [63] as well as van der Zee et al [64] proposed a set of phenotypes. However, there are still important obstacles to overcome. For instance, the Canoui-Poitrine types have only a modest interrater reliability and are therefore of limited use in clinical practice and research settings. The clinical

importance of the Martorell phenotypes have yet to be tested and the van der Zee types have not been statistically tested.

For future use to guide treatment, phenotypes must be clinically distinctive and have a high inter- and intra-rater reliability. The importance of this was recently demonstrated when Frew et al attempted to retrospectively label phenotypes to previous genetic HS publications [65]. A repeat of the process by another group resulted in a very different outcome [66].

At the moment, the problem shared by all these phenotypic classifications is that they are based on analysis of relatively few cases and most are retrospective. The data do not always include all of the phenotypic features and comorbidities. An agreed minimum HS phenotype dataset [67] may be needed to ensure that different datasets can be combined to increase statistical power.

Over recent years, the HS community has grown and we support efforts to study phenotypes in a prospective, large, international collaborative fashion with simultaneous collection of DNA for phenotype-genotype comparison [68].

## **SKIN MICROBIOTA AND HS**

(A. Nassif, J.C. Pascual, B. Perin)

Although HS was considered for many years to be purely inflammatory, recent extensive microbiology studies demonstrated the constant presence of commensal opportunistic bacterial flora within lesions, isolated in 4-7 days by culture [69] and confirmed by 16S-ribosomal-RNA-gene-amplicon-sequencing [6,13,70]. 16S-sequencing also demonstrated that microbiology correlates with Hurley's stage [12,71]. In half of Hurley stage I lesions, skin pathogens are isolated alone, either *Staphylococcus lugdunensis* (25%) or *Cutibacterium spp* (25%). In the other half of Hurley stage I lesions, in Hurley stages II and III lesions, the flora is polymicrobial, with predominance of strictly anaerobic species (*Prevotella* and *Porphyromonas* being the most abundant), but also includes aero-tolerant anaerobes: *Actinomyces spp*, *Streptococcus anginosus* group [6,69] and *Corynebacterium spp*, with lack of *Staphylococcus epidermidis* and *Cutibacterium spp*, usually present in control skin. Flora variety and richness increase with severity [12,69], *Fusobacterium*, *Campylobacter* and *Dialister* being encountered almost exclusively in Hurley stage III lesions [13]. Thus, clinical severity phenotype correlates with microbiological phenotype, suggesting different anti-microbial strategies according to severity. Using antibiotic combinations targeted against isolated flora resulted in complete remissions in Hurley stage I patients [71,72] and a dramatic improvement in patients with severe HS [73].

Furthermore:

- Two studies also demonstrated biofilm presence in HS lesions, mostly in severe forms [74,75], explaining constant relapses in previous scars.

- Dysbiosis was confirmed in uninvolved HS skin by 3 teams [6,76,77].

- An immune deficiency towards commensal gut flora was reported in patients with Crohn's disease carrying a NOD2 mutation [78], while some HS patients can present with both diseases.

All these data suggest a pathogenic role of the isolated flora, introducing a new concept of host-microbiome disease for HS. Instead of a purely auto-inflammatory process with an unclear mechanism, HS could be considered as "auto-infectious", due to a strictly cutaneous immune dysregulation. This deficiency would allow abnormal bacterial proliferation with toxin production and an inappropriate hyper-inflammatory host response, instead of bacterial elimination from the dermis. This model could open avenues for novel treatments and research for HS and associated diseases. Many questions remain concerning HS microbiology. Is early microbial shift contributing to follicular occlusion? Could loss of the "microbial shield" be partially restored with immunomodulation or microbiota transplantation, as explored in IBD?

Future microbiology studies should aim at demonstrating an abnormal transcriptomic response of skin/immune cells, when put into contact with HS lesional flora, with different levels of immune dysregulation/deficiency, potentially leading to different phenotypes and personalized strategies (Fig. 3).

## **COMPLEMENT, COVID-19 AND HS: WHAT WE LEARN FROM THIS ASSOCIATION?**

(E.J. Giamarellos-Bourboulis, G. Fabbrocini)

Complement split products, like complement 5a (C5a), mediate neutrophil chemotaxis and may play some role in HS pathogenesis [79,80]. Indeed, C1q, C2, and factor B were found to be upregulated and factor H, factor D and C7 downregulated in HS. C5a is produced through C5 cleavage which is mediated by C5 convertase. Activation of C5 convertase is converging towards all classical, alternative, and lectin pathways. C5a was significantly increased in the plasma of patients with HS. Surprisingly, C5a was lower among patients with Hurley stage III HS than Hurley stage I, driving the hypothesis that C5a is consumed as HS worsens. Excess TNF- $\alpha$  was produced by the peripheral blood mononuclear cells of patients upon enrichment of growth medium with plasma; this was significantly attenuated upon addition of the selective C5a blocker IFX-1 [81]. Twelve Hurley III patients refractory to anti-TNFs were treated with IFX-1.

Hidradenitis Suppurativa Clinical Response (HiSCR) was achieved in 75% at day 50 of treatment, whilst treatment responses were maintained three months after end of treatment in 83.3% [82]. Remarkably, the number of draining fistulas was significantly decreased, pointing towards a role of C5a in HS fistulization.

In recent months we have witnessed the spread of the novel coronavirus, SARS-CoV-2, which resulted in a global health emergency. COVID-19 caused by SARS-CoV-2 is associated with an acute respiratory illness that varies from mild to the acute respiratory distress syndrome (ARDS) [83]. Severe patients have complex immune dysregulation dominated either by macrophage activation syndrome or IL-6 hyperfunction [84,85]. Complement activation is a common if not fixed feature of ARDS. C5a is elevated and has been proposed as a marker of ARDS associated with sepsis, cytokine storm and multiorgan dysfunction [86,87]. Accumulating evidence shedding light on complement overactivation in severe COVID-19 turned attention to the therapeutic role of complement inhibitors [88]. The PANAMO trial that investigates the efficacy of IFX-1 in severe COVID-19 is already under way [89,90]. The reported beneficial responses of IFX-1 in HS generate thoughts on the C5a kinetic interplay mediating ARDS at acute activation and HS fistulization at chronic activation. At the same time, COVID-19 pandemic did not seem to affect the management of HS with biologics [91].

### **TISSUE T AND B CELLS IN HS**

(A.S. Byrd, J.W. Frew, W.P.F. Gulliver)

Observational studies in moderate-to-severe HS have identified up-regulated numbers of Th1, Th17, B cells, plasma cells, monocytes, dendritic cells and neutrophils in lesional HS tissue [15,18,92,93] (Fig. 4). The characteristics of cellular infiltrates in early and mild HS remain unclear. Transcriptomic studies (verified by immunohistochemistry, immune fluorescence and reverse transcription-polymerase chain reaction) demonstrate dramatic upregulation of genes associated with B and plasma cells (CD19, 25, 86, 138), T cells (CD3, 25), monocytes, dendritic cells (CD207, 303) and neutrophils [4,41]. Inflammatory cell trafficking cytokines including CXCL13, IL-6 and IL-8 are consistently upregulated in HS tissue [4,15,18,92-94]. HS patients have been shown to also have autoantibodies against citrullinated and extracellular matrix proteins [93]. Immunoglobulin producing plasma cells [95] and B cells [96] are major producers of IgD, IgG, IgM, ASCA, and anti-CCP antibodies [92,94,95] characterized in HS. The mechanisms of B cell-mediated activation of other cells and potential pathogenicity are yet to be determined. Th17

cells are identified in HS lesional tissue as associated with epidermal psoriasiform hyperplasia [15,18,92,94] and transepithelial neutrophil migration across tunnel epithelium [97].

Perifollicular and interfollicular mixed inflammatory cell infiltrates have been identified in the superficial dermis of mild lesions; however, these are major attractors to inflammatory infiltrates in HS, independent of lesional or perilesional status [97], different from the infiltrate found in mild disease. These observations suggest limitations to our knowledge and the importance of defining precise sample collections for mechanistic and clinical trial studies [98]. The mechanistic roles of these cells also remain speculative given the lack of reliable *in vitro*, *ex vivo* [99] and *in vivo* [100] disease models. The interaction between cell types is an area requiring further molecular and functional investigation. The chemokine signature of HS lesional tissue and dermal inflammatory architecture is suggestive of the possibility of tertiary lymphoid organs developing in chronic HS lesions [101]. This would fit with the known roles of complement, auto inflammation, and autoantibody development [15,18,92,93].

Overall, the characteristics of HS lesions are well-described but their interactions and mechanistic roles in disease activity and progression remains unclear. Priorities for future research into the mechanism of T and B cell function in HS include translational studies utilizing targeted monoclonal antibodies and examining the role of cells in mild and early disease.

## **CYTOKINES, CHEMOKINES AND HS**

(Y. Hayran, R.E. Hunger, A. Szegedi)

The excessive inflammatory response seen in lesional skin of HS is thought to be triggered by a combination of genetic, anatomical, immunological and environmental factors [94,102]. Thereby cytokines play a crucial role. Several studies showed that T cells and dendritic cells are responsible for the secretion of IL-23 and IL-12, leading to a Th17 predominant immune response and keratinocyte hyperplasia [16,23,94,102]. Especially IL-23 has been shown to induce IL-17 producing T helper cells, which infiltrate the dermis in HS lesions [103]. The IL-17 family of cytokines has been shown to be important in the pathogenesis of many autoimmune and autoinflammatory diseases especially also in psoriasis. IL-17 also plays an essential role in host defence against extracellular bacteria and fungi and it has been shown to increase the expression of skin antimicrobial peptides/alarmins, such as hBD2 and psoriasin [104]. Blocking IL-17 seems therefore a valid therapeutic approach also for HS.

During disease progression many different cytokines have been shown to be expressed in

increased levels. Especially TNF- $\alpha$  has been shown to be elevated. These findings resulted in the introduction of anti-TNF- $\alpha$  antibodies in the therapy of HS. As HS progresses, increased levels of TNF, IL-1, IL-17, S100A8, S100A9, caspase-1, and IL-10 appear in the tissue accompanied by a recruitment of neutrophils, mast cells and monocytes [7,15,94,102,105-108]. Recent evidence further points to autoinflammatory mechanism in HS. HS skin shows increased formation of neutrophil extracellular traps (NET). Intriguingly, immune responses to neutrophil and NET-related antigens have been linked to enhanced immune dysregulation and inflammation [93]. In combination with the strong type I interferon (IFN) signature in HS skin, these findings suggest a key involvement of the innate immune system in the pathogenesis of this disease [43,109]. As healing from the inflammatory process moves on, tissue scarring progresses [94,102,105]. The development of scarring and sinus tracts is associated with metalloproteinase-2, tumor growth factor(TGF)- $\beta$  and ICAM-1, with possible augmentation of TGF- $\beta$  and ICAM-1 signaling via specific components of the microbiome [94,102].

### **SEX HORMONES AND HS: WHAT'S NEW?**

(N.S. Chandran, G. Nikolakis)

The role of hormones in HS remains to be elucidated (Fig. 5). Gender predilections differ amongst races, as reported above. Sexual hormones and particularly androgens seem to play a role in the pathogenesis of the disease [110]. HS related-premenstrual flares [111], rare postmenopausal occurrence [112], improvement during pregnancy, post-partum flare-ups [113] and association of the disease with contraceptive pills with low estrogen/progesterone ratio suggest an endocrine pathophysiologic variable for the disease [114]. A current systematic review analyzed the therapeutic use of antiandrogens for HS, focusing on cyproterone acetate, spironolactone, finasteride and the antidiabetic drug metformin [115]. The yielded case series do not provide the evidence level for wide use of hormonal treatment for HS, which remains limited to female patients with menstrual abnormalities, signs of hyperandrogenism (seborrhea, acne, hirsutism, androgenetic alopecia) and/or increased serum androgens [116,117].

Obesity is one of the cardinal factors which predispose to HS and there seems to be an endocrine background fueling a latent proinflammatory state. In a cohort study from Denmark childhood BMI was positively and significantly associated with risk of HS development in adult age [118]. Returning to normal weight before puberty was found to reduce risks of HS to levels of not overweight children. Insulin resistance is common in HS [119]. Current molecular studies focus

on inflammation, while the correlation with hormonal treatments might be overlooked. The antidiabetic drug metformin exhibits an anti-inflammatory effect potentially reducing IL-6, TNF- $\alpha$  and IL-17 through decrease of Th17 cells, Treg and suppression of the NF $\kappa$ B complex.

Prospective and retrospective case series and case reports provide evidence for its use [120,121].

What is the window of opportunity for hormonal treatment of HS especially in the biologic era of HS? Could a major repurposing of available hormonal medications for cutaneous diseases contribute to HS treatment?

Indeed, there are cases of HS, where patients have lost response to antibiotics and still experience frequent flares of mild disease and do not qualify for adalimumab treatment or for other upcoming biologic treatments. In such cases, hormonal treatments might provide a cost-effective alternative. Moreover, certain comorbidities, such as severe heart insufficiency, do not allow the use of anti-TNF treatment. In such cases, alternative hormonal therapies, such as the diuretic spironolactone, which has antiandrogen properties, might hold promise.

## **CARDIOVASCULAR RISK FACTORS AND THEIR POTENTIAL CONTRIBUTION TO THE PATHOMECHANISM OF HS**

(M.A. González-López, T. Röhn, T. Tzellos)

There is strong epidemiologic evidence that cardiovascular risk factors appear at a significantly higher rate in HS patients as compared to healthy individuals. Among those risk factors, which are also commonly associated with metabolic syndrome, are obesity and in particular central obesity, insulin resistance, diabetes and dyslipidemia [122], as already highlighted above (Fig. 5). HS is significantly related to presence of carotid plaques and increased frequency of subclinical atherosclerosis and is associated with a significantly increased risk of adverse cardiovascular outcomes and all-cause mortality independent of measured confounders [123]. Notably, the risk of cardiovascular death is 58% higher in patients with HS than in patients with severe psoriasis [124]. Obesity affects the overall morbidity and prognosis of patients with HS and weight reduction can have a beneficial effect on HS prevalence and severity and even lead to spontaneous resolution of disease [125,126]. Obesity elicits a low-grade systemic inflammation caused by adipocytes that secrete metabolically active proinflammatory mediators known as adipokines. The secretion of adipokines has been found to be dysregulated in HS. These propagate the inflammatory cascade by recruiting macrophages to the adipose tissue, which release further pro-inflammatory mediators. In this regard, it has been reported that the adipokines resistin and leptin were found increased in



patients' serum and adiponectin was decreased [127]. High systemic inflammatory burden may cause a state of insulin resistance in inflamed tissues which is causally linked to endothelial dysfunction and atherosclerosis [128]. As a result, reduced adiponectin and increased resistin serum levels have been identified as surrogate biomarkers for insulin resistance in patients with HS [129]. Resistin and visfatin were proposed to be involved in HS pathogenesis [130]. Moreover, nutritional excess in metabolic syndrome can lead to adipose tissue expansion and adipocyte hypertrophy associated with increased release of inflammatory mediators. In subcutaneous adipose tissue, this can cause cutaneous inflammatory responses but also spill-over of inflammatory mediators into the systemic circulation contributing to progression of the metabolic syndrome [129,131].

Among the inflammatory mediators produced by adipocytes are arachidonic acid derived polyunsaturated fatty acids (PUFAs) of the  $\omega$ 6 class, the so-called eicosanoids. High fat diet and in particular western diet containing a high  $\omega$ -6/ $\omega$ -3 ratio can further enhance the release of arachidonic acid-derived lipid mediators by adipocytes [132,133]. Adipocytes are among the few non-leukocyte cell types that possess the enzymatic machinery to produce the pro-inflammatory eicosanoid leukotriene B4 (LTB4), which confers not only macrophage and neutrophil infiltration and activation but also contributes to insulin resistance and has been implicated with increased cardiovascular risk [134,135]. Interestingly, comprehensive PUFA lipidomics analysis of HS skin lesions has recently identified LTB4 as the most dominantly upregulated pro-inflammatory lipid mediator in HS lesions, produced mainly by lesional macrophages [136]. The potential contribution of pro-inflammatory LTB4 to dysregulated innate immunity in HS is currently investigated in clinical trials and it is tempting to speculate that elevated levels of this inflammatory mediator may also contribute to metabolic syndrome associated comorbidities in HS.

## **SMOKING AND HS**

(Q. Ju, M.P. Konstantinou)

HS is a tobacco-related skin disease [137]. The role and mechanisms of cigarette smoke (CS) in HS remains speculative. CS is composed of numerous chemicals, whereas nicotine, benzopyrenes and dioxin-like compounds are the most well-known .

The natural ligands of nicotine are the nicotinic acetylcholine receptors (nAChRs), which are identified in skin keratinocytes, sebocytes and immune cells constituting the non-neuronal cholinergic system [138]. Many HS patients are heavy smokers, since they use tobacco to alleviate

symptoms of anxiety and depression [139]. Variability in genes that encode nAChR subunits are associated with multiple smoking phenotypes [140] and could explain a certain profile of HS smokers. Nicotine negatively impacts keratinocyte functions, including the stimulation of chemotaxis, cytokine release and oxidative stress [141] and also stimulates keratinocyte differentiation and epithelial hyperplasia [142]. In epidermis of patients with HS, there is a strong expression of nAChR around the pilosebaceous unit leading to infundibular epithelial hyperplasia and follicular plugging [143]. Furthermore, studies have revealed highly potent effects of the cholinergic system on sebocyte proliferation and lipid production *in vitro*, but the role in HS is unclear [144].

In addition, CS appears to further stimulate the dysbiosis-driven aberrant activation of the innate immune system in HS. Nicotine, as an alkaloid, appears to promote growth of *Staphylococcus aureus*, thus modifying the microbiome [145] and inhibits the synthesis of antimicrobial peptides, such as hBD2, rendering the follicle more susceptible to bacterial invasion [146].

Smokers in comparison with non-smokers exhibit higher serum levels of pro-inflammatory cytokines and TNF- $\alpha$  [147]. Human bronchial epithelial cells release IL-1 $\beta$  and express caspase-1 via stimulation of Toll-like receptors, after incubation with CS [148]. In mouse models, nicotine was found to activate NLP3 inflammasome [149]. Smoking adversely affects the Th17/Treg balance. It has been associated with increased expression of Th17 cells, IL-17 expression and impaired numbers or function of Tregs [150]. Furthermore, downregulation of Notch pathway gene expression has been reported in association with smoking [151].

Finally, dioxin-like compounds and benzopyrenes of CS trigger *in vivo* and *in vitro* the aryl hydrocarbon pathway which is present on keratinocytes, sebocytes and immune cells [152,153]. Exposure to extremely high concentrations of dioxins induces hyperkeratinization of the pilosebaceous unit and a metaplastic response of the sebaceous glands producing clinical lesions of chloracne [154], whose clinical features are highly similar to the “smokers’ boils” in HS [155]. The possible actions of CS in HS is summarized in Fig. 6.

## **HAIR FOLLICLE STEM CELL REPLICATION DISORDER VS. ALOPECIA AREATA COMORBIDITY VS APOCRINE GLAND DISEASE: WHERE IS THE EVIDENCE?**

(S. Hue, J.S. Kirby, R. Paus)

From its naming, the apocrine gland was implicated as a major contributor in HS pathogenesis. In contrast, histopathologic and molecular studies indicate significant involvement of the hair

follicle with secondary apocrine gland injury [156-159]. There are a number of changes in the hair follicle including an occluding spongiform inflammation in the infundibulum with predominantly T cells and infundibular disintegration in early lesions [157,160]. Hair follicle keratinocytes also produce more proinflammatory cytokines and have an altered pattern of antimicrobial peptide production [15]. Impaired hair follicular stem cells (hfSCs) homeostasis leading to an increased proliferation induces stress replication and stimulates type I IFN production which participates to the strong inflammatory skin reaction [161]. Dysregulation of the T reg/Th17 axis may also impact hfSCs and subsequently lead to structural instability of the infundibulum [95,162]. Thus, the follicle cells are altered toward a proinflammatory state that may underlie follicular instability and promote the inflammatory response.

HS pathogenesis involves both hair follicle disruption and a robust immune response [163]; however, the hfSCs at the bulge are immune privileged, lacking MHC I expression. It is theorized that alopecia areata (AA) is caused by the loss of immune privilege at the hair follicle either due to disruption of the hair follicle epithelium or a dysregulated immune response [164,165]. HS has been associated with multiple inflammatory and autoimmune diseases, including AA [166,167]. In a Korean study, AA was more common in patients with HS than in patients without HS (adjusted odds ratio=1.35) [166]. Similarly, AA was also more common in patients with HS (adjusted odds ratio=1.99) in a US study [168]. The lesions of HS and AA have considerable overlap in inflammatory cytokines, including TNF- $\alpha$ , IL-17, IFNs, chemokine ligands 9 and 10, granzyme B, and others [43,164]. It is not known yet if inflammatory phenotype of hfSC in HS leads to the loss of hair follicle progenitor cells promoting AA, however, investigating the association between these two diseases may help elucidate the pathogenesis of each.

#### **WHAT WE LEARN FROM „ECTOPIC“ AND „SYNDROMIC“ HS?**

(F. Benhadou, P. Guillem)

Recent attempts to classify HS phenotypes have distinguished ‘typical’ and ‘atypical’ HS [169]; syndromic and ectopic HS belong to the latter. Auto-inflammatory syndromes associated with HS and/or acne are rare [170]. Their common pathogenic feature is an over-activation of innate immunity with aberrant activation of IL-1 and IL-17/TNF- $\alpha$  axis resulting in the formation of neutrophilic infiltrate [171]. The onset of HS as part of their skin involvement raised the hypothesis to reconsider HS as a Th17-driven auto-inflammatory disease. Interestingly, mutations in *PSTPIP1* gene, that encodes for components of the inflammasome, a cytosolic multiprotein

oligomers responsible for the IL-1 synthesis have been described in 2 forms of syndromic HS [19], the PASH syndrome [19,20,172] and the PAPASH syndrome defined by the PASH triad of pyoderma gangrenosum, acne and HS and the presence of pyogenic arthritis [173]. The addition of either spondylarthritis (PASS) [174] or psoriatic arthritis (PsAPASH) [175] to the triad have also been described but associated mutations are not identified. It is crucial to increase the awareness about syndromic HS and the use of drugs that target IL1-TNF- $\alpha$ /IL-17 may represent attractive therapeutic options [176].

In opposite, ectopic forms of HS do not develop regarding typical intertriginous and apocrine gland-bearing skin areas and may affect convex and/or apocrine gland-free areas (ear, chest, neck, nape, leg). Local mechanical stress represents the main triggering factor [177,178] including friction, shearing and pressure. Mechanical follicular occlusion could be a mechanism by which local trauma would promote HS onset and molecular signaling underlying mechano-transduction should be explored. Interestingly,  *$\gamma$ -secretase* mutations causing impaired Notch pathway and thereby promoting Th17-driven inflammation have been reported in small numbers of HS cases [26]. Whether mechanical-induced alterations in the Notch pathway could also result in apocrine metaplasia of eccrine glands could be discussed [179], since Notch has been identified as a regulator of skin stem cells fate [180].

## **HOW ITCH AND PAIN OCCUR IN HS?**

(Ł. Matusiak, J. Szepietowski)

It is obvious that pain accompanies HS, as the vast majority (95.2-97.1%) of patients report it during the disease course [181,182]. It is perceived as the most troublesome symptom of HS [181]. Although one decade ago HS was not considered a pruritic disease, itch is also a common HS-associated symptom (62.1-77.5% of reporting patients) that adversely affects patients' quality of life [181-183]. Of note, the co-occurrence rate of pain and itch in one location was surprisingly high, as reported by 59.5-74.9% of patients [181,182].

It could be assumed that both, acute pain observed during flare-ups and itch frequently reported in the initial phase of HS (as a prodrome) have a noci/-pruriceptive character, linked to the local activation of cells of the innate and adaptive immune systems, with pivotal roles for proinflammatory cytokines and various chemokines, which can bind directly to their specific receptors on the peripheral terminals of the afferent nociceptive neurons [9,184-187]. The unrestricted and chronic immune response observed in HS leads to pyroptosis resulting in

irreversible tissue destruction and scar development. This could alter the character of subjective symptoms and lead to the development of neuropathic pain and/or itch being a consequence of the nervous system structures damage, or sometimes of prolonged, unremitting nerve stimulation. Neuropathic pain and itch are often associated with each other, and hypersensitization to stimuli is present in both pain and itch of neuropathic origin [188]. Recent considerations regarding chronic pain in HS tried to explain this phenomenon through the process of central sensitization, which is the effect of first-order afferent nociceptive neuron repeated and increased activation during chronic and recurrent inflammation [189]. HS may promote the central sensitization development through its highly expressed systemic inflammatory burden. Soluble TNF- $\alpha$  receptor, IL-6, IL-17 and IL-23 have been found to increase the blood-brain and blood-spinal cord barrier permeability, potentially aiding the infiltration of immune cells and inflammatory mediators into the central nervous system [190]. Here, these inflammatory cytokines may influence synaptic transmission analogous to locally released cytokines [185,187,189]. Therefore, not only analgesics or selective serotonin reuptake inhibitors, but also anti-inflammatory/immunomodulating therapies, could play an important role and significantly alleviate the intensity of pain and itch sensation [191].

## **PATHOGENESIS-ASSOCIATED FUTURE THERAPIES**

(A.B. Kimball, C.C. Zouboulis)

Our modern understanding of the pathogenetic pathways that drive hidradenitis suppurativa is rapidly emerging. New tools that allow the characterization of the microbiome, proteome, and transcriptome are opening up new avenues of investigation [192]. But perhaps most interesting is the *in vivo* exploration of new targeted immunologic therapies. The use of new agents is likely to accelerate our understanding as they present the opportunity to use clinical effectiveness to validate relevant patterns. Indeed, the pathogenetic patterns of HS are likely to be elucidated from bedside to bench, even as they are from bench to bedside. Conducting inclusive, long-term, controlled multi-center clinical trials investigating different biological agents or drugs with ancillary analyses of transcriptomes will leap forward the HS patient journey. These will build the foundations to fully integrate our HS transcriptome knowledge with clinical records, epidemiologic and demographic factors [98].

To date, however, HS remains a “messy” immunologic disease. Many cytokines have been identified in histologic samples, but the sequence of the pattern and the key initiators are still a work in progress. A recent paper by Frew et al [65] demonstrated no consistent cytokine patterns.

However, the inhibition of TNF- $\alpha$ , IL-1 and IL-17 has been validated in clinical trials as relevant. Other transcriptomic studies have reaffirmed their role and have additionally suggested that androgen receptor, interferon- $\gamma$ , IL-6, Growth Arrest-Specific 6, Glial Cell Derived Neurotrophic Factor and Hepatocyte Growth Factor are viable targets using currently available agents (Table 1). There is also early data suggesting that IL-23, C5a and Janus kinase inhibitors may be successful targets.

As both targeted and multimodality approaches are tested, it will be interesting to see whether, given the high inflammatory load, a multimodality approach is more effective for induction, and more targeted approaches are useful for maintenance. Generally, effective treatment of HS with targeted anti-TNF agents has required higher doses than other skin diseases even with weight-based dosing [193,194]. Moreover, the cytokine profile of lesional skin suggests tamping down other parts of the inflammatory cascade simultaneously could be useful. In any event, the number of effective agents currently under study is enormously encouraging and will lead us to better understand the disease and help our patients.

#### **WHAT ARE WE EXPECTING IN THE FUTURE?**

(M.A. Lowes, C.C. Zouboulis)

Although a huge amount of knowledge has accumulated in the last 15 years, including simplified diagnostic criteria for early recognition of the disease [195], we are just at the beginning of understanding HS and being able to treat it effectively. Future targets are emerging. Highly sophisticated molecular studies, such as next generation sequencing analyses, will further increase the molecular understanding of HS etiology, which already has a solid basis due to current relevant studies [4,15,40-43]. Through such reports a clearer association of different clinical phenotypes [62-65] with relevant molecular expression patterns may be recognized, which will fulfil the requirements of personalized medicine in HS. Clinical and laboratory biomarkers may accompany improved clinical outcome measures [10,11,196] for better monitoring of the disease course. Robust *ex vivo* models might corroborate clinical data [197]. Clearer documentation and newer diagnostic techniques, such as standardized photography, ultrasound and thermography [66,198-200] together with apps for prospective evaluation of relevant patient outcome measures, such as daily assessment of pain [194], may lead towards the digitalization and objectification of clinical follow-up. Ultimately, successful early HS treatment will aim to spare HS patients from progression of the disease and preventing large surgical excisions, complications and recurrence.

## Data Availability Statement

The authors confirm the absence of shared data.

**Conflict of interest:** All authors declare that none of the mentioned conflicts of interest had any influence to this manuscript. **CCZ** has received thematically relevant honoraria from AbbVie as advisor and conference speaker and from Idorsia, Incyte, Inflarx, Janssen-Cilag, Novartis, Regeneron and UCB as advisor. His departments have received grants from AbbVie, AOTI, Astra Zeneca, Galderma, Inflarx, Naos-Bioderma, Novartis, PPM and UCB for his participation as clinical investigator. **NSC** has received fees from AbbVie, Johnson & Johnson and Sanofi for participation in advisory boards, investigator fees for clinical trials from AbbVie, Novartis and Sanofi and speaker honoraria from Galderma, Johnson & Johnson and LEO. **EJG-B** has received honoraria from Abbott, Angelini, bioMérieux, InflaRx, MSD and XBiotech; independent educational grants from AbbVie, Abbott, Astellas, AxisShield, bioMérieux, InflaRx, ThermoFisher Brahms, and XBiotech; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis). **JWF** was supported in part by a grant (no. UL1 TR001866) from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) Program. **HF** has received honoraria for speaker and/or consultancy from AbbVie, Boehringer-Ingelheim, Celgene, Eisai, Eli Lilly, Novartis, Janssen-Cilag, Marho, Sanofi, Taiho, Tanabe-Mitubishi and UCB. **PG** received honoraria from AbbVie and Novartis as a consultant and provided lectures for AbbVie, Brothier, Cicaplus, Coloplast, Inresa and Novartis. **MAG-L** reports consultation fees/participation in company-sponsored speaker's bureau from Abbvie. **WPF** reports grants and research support by AbbVie, Amgen, Eli Lilly, Novartis, Pfizer; honoraria for invited talks and consultation by AbbVie, Actelion, Amgen, Arylide, Bausch Health, Boehringer, Celgene, Cipher, Eli Lilly, Galderma, Janssen, LEO, Novartis, PeerVoice, Pfizer, Sanofi, Tribute, UCB, Valeant; and study fees from clinical trials by AbbVie, Asana, Astellas, Boehringer-Ingelheim, Celgene, Corrona/National Psoriasis Foundation, Devonian, Eli Lilly, Galapagos, Galderma, Janssen, LEO, Novartis, Pfizer, Regeneron, UCB. **IH** reports consultation fees/participation in advisory board of

AbbVie; grant/research funding from AbbVie, Allergan, Bayer, Bristol-Myers Squibb, Clinuvel, Estee Lauder, Ferndale, Galderma, GE, Incyte, Janssen-Cilag, Johnson & Johnson, Lencicura, L'Oreal, L.P., Merck, PCORI, Pfizer, Unigen; and consulting fees from Incyte. **BH** reports fees from AbbVie, Akari, Celgene, Janssen-Cilag, Novartis and UCB for advisory boards, AbbVie, Janssen-Cilag, LEO, Novartis, Philips, Roche, Regeneron, Sanofi and UCB for consultations; AbbVie, Akari, Celgene, Janssen-Cilag, Novartis and Solenne for investigator initiative studies, and AbbVie and Janssen-Cilag for educational grants, which fees were payed to the institution. **REH** has received thematically relevant honoraria from AbbVie and Novartis. **JRI** is a consultant to Kymera Therapeutics, Novartis, UCB and Viela Bio, and has received a speaker's honorarium from UCB and travel expenses from AbbVie and UCB. **GBEJ** has received honoraria from AbbVie, Chemocentryx, Coloplast, Incyte, Inflarx, Kymera Therapeutics, LEO, Novartis and UCB for participation on advisory boards, and grants from Abbvie, Astra-Zeneca, Inflarx, Janssen-Cilag, LEO, Novartis, Regeneron and Sanofi for participation as an investigator, and received speaker honoraria from AbbVie, Boehringer-Ingelheim, Galderma and Novartis. He has also received unrestricted departmental grants from LEO and Novartis. **JSK** reports fees from AbbVie, Incyte, Viela Bio for advisory boards, AbbVie, ChemoCentryx, Incyte, Novartis, Bayer, UCB for consultations and AbbVie as speaker. **MPK** is investigator for Abbvie, Boehringer-Ingelheim, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB and has received honoraria from AbbVie, Eli Lilly, LEO and Novartis. **ABK** is consultant and Investigator for Abbvie, Eli Lilly, Janssen-Cilag, Novartis, Pfizer and UCB, consultant for Kymera Therapeutics, investigator for ChemoCentryx and Board of Directors for Almirall and received fellowship funding from AbbVie and Janssen-Cilag. **MAL** has served on the advisory boards for Abbvie, Janssen-Cilag, and Viela Bio, and consulted for Almirall, BSN, Incyte, Janssen-Cilag, Kymera Therapeutics, and XBiotech. **ASM** is supported by funds from the National Institute of Health (R01AI139207) and the Department of Dermatology of Duke University. She reports fees from Silab (consultancy, grant, speaker honorarium). Silab had no involvement, influence or decision on the content of this manuscript or the decision to publish. ASM also reports fees from the LEO Foundation (Scientific Evaluation Committee) and her spouse is employed at Precision Biosciences and holds stock and stock options in this company. **AM** has served as a consultant for and received speaker fees from AbbVie, Celgene, Eli Lilly, Isdin, Janssen-Cilag, LEO, MSD, Novartis, Pfizer and UCB. **LM** reports personal fees from AbbVie, Amgen, Galapagos, InflaRx, Janssen-Cilag, LEO, Menlo, Novartis, Pfizer, Pierre Fabre, Regeneron, Trevi and UCB. **ANdC** is an AstraZeneca employee



and owns AstraZeneca stocks. AstraZeneca had no involvement, influence or decision on the content of this manuscript. **LAVO** is supported by funds from the National Institute of Health (K12D085850). She is an investigator for ChemoCentryx. **JCP** reports honoraria from AbbVie for participation on advisory boards. **MMO** received honoraria from AbbVie for speaker services, and from AbbVie, Azora, Boehringer Ingelheim, Gilead, GSK, Incyte, Innovaderm, InflaRx, Genentech, Pfizer, Regeneron, Seattle Genetics for consultant services. **RP** is founder and CEO of Monasterium Laboratory Skin & Hair Research Solutions. **EPP** received honoraria from AbbVie, Amgen, Celgene, Galderma, Janssen-Cilag, Novartis and Pfizer for participation as a speaker and serving on advisory boards and investigator-initiated grants (paid to the Erasmus MC) from AbbVie, AstraZeneca, Janssen-Cilag and Pfizer. **TAR** is associated with Novartis Institutes for Biomedical Research and is employee of Novartis Pharma AG. **JCS** reports personal fees from AbbVie, Amgen, Galapagos, InflaRx, Janssen-Cilag, LEO, Menlo, Novartis, Pierre Fabre, Regeneron, Sandoz, Sanofi, Sienna, Trevi and UCB. **AS** has received thematically relevant honoraria from AbbVie, Eli Lilly, Janssen-Cilag, LEO, Novartis, Sanofi and UCB and was supported by the Hungarian National Research, Development and Innovation Fund (K-128250). **TT** reports fees from AbbVie, UCB and Sanofi (consultancy, speaker honorarium). **HHvdZ** reports fees from AbbVie and InflaRx. **FB, ASB, GF, YH, SH, QJ, MPK, AVM, AN, EN, GN, BP** and **BW** declare no conflict of interest.

#### **Author contribution statement**

Christos C. Zouboulis wrote a part of the manuscript, read and approved the final manuscript.

Farida Benhadou wrote a part of the manuscript, read and approved the final manuscript.,

Angel S. Byrd wrote a part of the manuscript, read and approved the final manuscript.

Nisha S. Chandran wrote a part of the manuscript, read and approved the final manuscript.

Evangelos J. Giamarellos-Bourboulis wrote a part of the manuscript, read and approved the final manuscript.

Gabriella Fabbrocini wrote a part of the manuscript, read and approved the final manuscript.

John W. Frew wrote a part of the manuscript, read and approved the final manuscript.

Hideki Fujita wrote a part of the manuscript, read and approved the final manuscript.

Marcos A. González-López wrote a part of the manuscript, read and approved the final manuscript.

Philippe Guillem wrote a part of the manuscript, read and approved the final manuscript.

Wayne P. F. Gulliver wrote a part of the manuscript, read and approved the final manuscript.  
Iltefat Hamzavi wrote a part of the manuscript, read and approved the final manuscript.  
Yildiz Hayran wrote a part of the manuscript, read and approved the final manuscript.  
Barbara Hórvath wrote a part of the manuscript, read and approved the final manuscript.  
Sophie Hüe wrote a part of the manuscript, read and approved the final manuscript.  
Robert E. Hunger wrote a part of the manuscript, read and approved the final manuscript.  
John R. Ingram wrote a part of the manuscript, read and approved the final manuscript.  
Gregor B.E. Jemec wrote a part of the manuscript, read and approved the final manuscript.  
Qiang Ju wrote a part of the manuscript, read and approved the final manuscript.  
Alexa B. Kimball wrote a part of the manuscript, read and approved the final manuscript.  
Joslyn S. Kirby wrote a part of the manuscript, read and approved the final manuscript.  
Maria P. Konstantinou wrote a part of the manuscript, read and approved the final manuscript.  
Michelle A. Lowes wrote a part of the manuscript, read and approved the final manuscript.  
Amanda S. MacLeod wrote a part of the manuscript, read and approved the final manuscript.  
Antonio Martorell wrote a part of the manuscript, read and approved the final manuscript.  
Angelo V. Marzano wrote a part of the manuscript, read and approved the final manuscript.  
Łukasz Matusiak wrote a part of the manuscript, read and approved the final manuscript.  
Aude Nassif wrote a part of the manuscript, read and approved the final manuscript.  
Elena Nikiphorou wrote a part of the manuscript, read and approved the final manuscript.  
Georgios Nikolakis wrote a part of the manuscript, read and approved the final manuscript.  
André Nogueira da Costa wrote a part of the manuscript, read and approved the final manuscript.  
Martin M. Okun wrote a part of the manuscript, read and approved the final manuscript.  
Lauren A.V. Orenstein wrote a part of the manuscript, read and approved the final manuscript.  
José Carlos Pascual wrote a part of the manuscript, read and approved the final manuscript.  
Ralf Paus wrote a part of the manuscript, read and approved the final manuscript.  
Benjamin Perin wrote a part of the manuscript, read and approved the final manuscript.  
Errol P. Prens wrote a part of the manuscript, read and approved the final manuscript.  
Till A. Röhn wrote a part of the manuscript, read and approved the final manuscript.  
Andrea Szegedi wrote a part of the manuscript, read and approved the final manuscript.  
Jacek C. Szepietowski wrote a part of the manuscript, read and approved the final manuscript.  
Thrasylvoulos Tzellos wrote a part of the manuscript, read and approved the final manuscript.  
Baoxi Wang wrote a part of the manuscript, read and approved the final manuscript.  
Hessel H. van der Zee wrote a part of the manuscript, read and approved the final manuscript.

## REFERENCES

1. H. Kurzen, I. Kurokawa, G. B. E. Jemec, L. Emtestam, K. Sellheyer, E. J. Giamarellos-Bourboulis, I. Nagy, F. G. Bechara, K. Sartorius, J. Lapins, D. Krahl, P. Altmeyer, J. Revuz, C. C. Zouboulis, *Exp. Dermatol.* 2008, **17**, 455.
2. A. Garg, E. Neuren, D. Cha, J. S. Kirby, J. R. Ingram, G. B. E. Jemec, S. Esmann, L. Thorlacius, B. Villumsen, V. del Marmol, A. Nassif, M. Delage, T. Tzellos, D. Moseng, Ø. Grimstad, H. Naik, R. Micheletti, S. Guilbault, A. P. Miller, I. Hamzavi, H. van der Zee, E. Prens, N. Kappe, C. Ardon, B. Kirby, R. Hughes, C. C. Zouboulis, G. Nikolakis, F. G. Bechara, L. Matusiak, J. Szepietowski, A. Glowaczewska, S. D. Smith, N. Goldfarb, S. Daveluy, C. Avgoustou, E. Giamarellos-Bourboulis, S. Cohen, Y. Soliman, E. G. Brant, O. Akilov, C. Sayed, J. Tan, A. Alavi, M. A. Lowes, J. C. Pascual, H. Riad, S. Fisher, A. Cohen, S. Y. Paek, B. Resnik, Q. Ju, L. Wang, A. Strunk, *J. Am. Acad. Dermatol.* 2020, **82**, 366.
3. S. Reddy, A. Strunk, A. Garg, *JAMA. Dermatol.* 2019, **155**, 797.
4. C. C. Zouboulis, A. Nogueira da Costa, E. Makrantonaki, X. X. Hou, D. Almansouri, J. T. Dudley, H. Edwards, B. Readhead, O. Balthasar, G. B. E. Jemec, N. G. Bonitsis, G. Nikolakis, D. Trebing, K. C. Zouboulis, A. M. Hossini, *J. Eur. Acad. Dermatol. Venereol.* 2020, **34**, 846.
5. S. Duchatelet, S. Miskinyte, M. Delage, M.-N. Ungeheuer, T. Lam, F. Benhadou, V. Del Marmol, A. R. J. V. Vossen, E. P. Prens, O. Cogrel, M. Beylot-Barry, C. Girard, J. Vidil, O. Join-Lambert, M. Parisot, P. Nitschké, S. Hanein, S. Fraitag, D. Bessis, G. Damiani, A. Altomare, Y.-H. Liao, G. Nikolakis, C. C. Zouboulis, A. Nassif, A. Hovnanian, *J. Invest. Dermatol.* 2020 [online ahead of print]
6. H. C. Ring, J. Thorsen, D. M. Saunte, B. Berit, L. Bay, P. Theut Riis, N. Larsen, L. O'Brien Andersen, H. V. Nielsen, I. M. Miller, T. Bjarnsholt, K. Fuursted, G. B. Jemec, *JAMA. Dermatol.* 2017, **153**, 897.
7. H. H. van der Zee, L. de Ruiten, D. G. van den Broecke, W. A. Dik, J. D. Laman, E. P. Prens, *Br. J. Dermatol.* 2011, **164**, 1292.
8. A. B. Kimball, M. M. Okun, D. A. Williams, A. B. Gottlieb, K. A. Papp, C. C. Zouboulis, A. W. Armstrong, F. Kerdel, M. H. Gold, S. B. Forman, N. J. Korman, E. J. Giamarellos-Bourboulis, J. J. Crowley, C. Lynde, Z. Reguijai, E.-P. Prens, E. Alwawi, N. M. Mostafa, B. Pinsky, M. Sundaram, Y. Gu, D. M. Carlson, G. B. E. Jemec, *N. Engl. J. Med.* 2016, **375**, 422.

9. R. Sabat, G. B. E. Jemec, Ł. Matusiak, A. B. Kimball, E. Prens, K. Wolk, *Nat. Rev. Dis. Primers* 2020, **6**, 18.
10. C. C. Zouboulis, T. Tzellos, A. Kyrgidis, G. B. E. Jemec, F. G. Bechara, E. J. Giamarellos-Bourboulis, J. R. Ingram, T. Kanni, I. Karagiannidis, A. Martorell, L. Matusiak, A. Pinter, E. P. Prens, D. Presser, S. Schneider-Burrus, E. von Stebut, J. C. Szepietowski, H. H. van der Zee, S. M. Wilden, R. Sabat, on behalf of the EHSF Investigator Group, *Br. J. Dermatol.* 2017, **177**, 1401.
11. L. Thorlacius, J. R. Ingram, B. Villumsen, S. Esmann, J. S. Kirby, A. B. Gottlieb, J. F. Merola, R. Dellavalle, S. M. Nielsen, R. Christensen, A. Garg, G. B. E. Jemec, *Br. J. Dermatol.* 2018, **179**, 642.
12. H. B. Naik, J. H. Jo, M. Paul, H. H. Kong, *J. Invest. Dermatol.* 2020, **140**, 922.
13. H. Guet-Revillet, J.-P. Jais, M.-N. Ungeheuer, H. Coignard-Biehler, S. Duchatelet, M. Delage, T. Lam, A. Hovnanian, O. Lortholary, X. Nassif, A. Nassif, O. Join-Lambert, *Clin. Infect. Dis.* 2017, **65**, 282.
14. T. H. Mogensen, *Clin. Microbiol. Rev.* 2009, **22**, 240.
15. C. Hotz, M. Boniotto, A. Guguin, M. Surenaud, F. Jean-Louis, P. Tisserand, N. Ortonne, B. Hersant, R. Bosc, F. Poli, H. Bonnabau, R. Thiébaud, V. Godot, P. Wolkenstein, H. Hocini, Y. Lévy, S., *J. Invest. Dermatol.* 2016, **136**, 1768.
16. R. Thomi, C. Schlapbach, N. Yawalkar, D. Simon, D. Yerly, R. E. Hunger, *Exp. Dermatol.* 2018, **27**, 172.
17. C. A. Constantinou, G. E. Fragoulis, E. Nikiphorou, *Ther. Adv. Musculoskelet. Dis.* 2019, **11**, 1759720X19895488.
18. E. Witte-Handel, K. Wolk, A. Tsaousi, M. L. Irmer, R. Mößner, O. Shomroni, T. Lingner, K. Witte, D. Kunkel, G. Salinas, S. Jodl, N. Schmidt, W. Sterry, H.-D. Volk, E. J. Giamarellos-Bourboulis, A. Pokrywka, W.-D. Döcke, S. Schneider-Burrus, R. Sabat, *J. Invest. Dermatol.* 2019, **139**, 1294.
19. A. V. Marzano, I. Ceccherini, M. Gattorno, D. Fanoni, F. Caroli, M. Rusmini, A. Grossi, C. De Simone, O. M. Borghi, P. L. Meroni, C. Crosti, M. Cugno, *Medicine (Baltimore)* 2014; **93**: e187.
20. A. V. Marzano, G. Damiani, I. Ceccherini, E. Berti, M. Gattorno, M. Cugno, *Br. J. Dermatol.* 2017, **176**, 1588.
21. D. L. Kastner, I. Aksentievich, R. Goldbach-Mansky, *Cell* 2010, **140**, 784.

22. P. M. Tricarico, M. Boniotto, G. Genovese, C. C. Zouboulis, A. V. Marzano, S. Crovella, *Front. Immunol.* 2019, **10**, 892.
23. C. Schlapbach, T. Hanni, N. Yawalkar, R. E. Hunger, *J. Am. Acad. Dermatol.* 2011, **65**, 790.
24. B. C. Melnik, S. M. John, W. Chen, G. Plewig, *Br. J. Dermatol.* 2018, **179**, 260.
25. L. Brandao, R. Moura, P. M. Tricarico, R. Gratton, G. Genovese, C. Moltrasio, S. Garcovich, M. Boniotto, S. Crovella, A. V. Marzano, *J. Dermatol. Sci.* 2020, **99**, 17.
26. B. Wang, W. Yang, W. Wen, J. Sun, B. Su, B. Liu, D. Ma, D. Lv, Y. Wen, T. Qu, M. Chen, M. Sun, Y. Shen, X. Zhang, *Science* 2010, **330**, 1065.
27. Y. Liu, M. Gao, Y.-M. Lv, X. Yang, Y.-Q. Ren, T. Jiang, X. Zhang, B.-R. Guo, M. Li, Q. Zhang, P. Zhang, F.-S. Zhou, G. Chen, X.-Y. Yin, X.-B. Zuo, L.-D. Sun, X.-D. Zheng, S.-M. Zhang, J.-J. Liu, Y. Zhou, Y.-R. Li, J. Wang, J. Wang, H.-M. Yang, S. Yang, R.-Q. Li, X.-J. Zhang, *J. Invest. Dermatol.* 2011, **131**, 1570.
28. Y. Nomura, T. Nomura, K. Sakai, K. Sasaki, Y. Ohguchi, O. Mizuno, H. Hata, S. Aoyagi, R. Abe, Y. Itaya, M. Akiyama, H. Shimizu, *Br. J. Dermatol.* 2013, **168**, 206.
29. M. Pavlovsky, O. Sarig, M. Eskin-Schwartz, N. Malchin, R. Bochner, J. Mohamad, A. Gat, A. Peled, A. Hafner, E. Sprecher, *Br. J. Dermatol.* 2018, **178**, 502.
30. S. Miskinyte, A. Nassif, F. Merabtene, M.-N. Ungeheuer, O. Join-Lambert, J.-P. Jais, A. Hovnanian, *J. Invest. Dermatol.* 2012, **132**, 1728.
31. A. E. Pink, M. A. Simpson, G. W. Brice, C. H. Smith, N. Desai, P. S. Mortimer, J. N. W. N. Barker, R. C. Trembath, *J. Invest. Dermatol.* 2011, **131**, 1568.
32. U. Ratnamala, D. Jhala, N. K. Jain, N. M. Saiyed, M. Raveendrababu, M. V. Rao, T. Y. Mehta, F. M. Al-Ali, K. Raval, S. Nair, N. K. Chandramohan, M. R. Kuracha, S. K. Nath, U. Radhakrishna, *Exp. Dermatol.* 2016, **25**, 314.
33. S. Chen, P. Mattei, J. You, N. L. Sobreira, G. A. Hinds, *JAMA. Dermatol.* 2015, **151**, 668.
34. M. Liu, J. W. Davis, K. B. Idler, N. M. Mostafa, M. M. Okun, J. F. Waring, *Br. J. Dermatol.* 2016, **175**, 414.
35. D. J. Ralser, F. B. Basmanav, A. Tafazzoli, J. Wititsuwannakul, S. Delker, S. Danda, H. Thiele, S. Wolf, M. Busch, S. A. Pulimood, J. Altmüller, P. Nürnberg, D. Lacombe, U. Hillen, J. Wenzel, J. Frank, B. Odermatt, R. C. Betz, *J. Clin. Invest.* 2017, **127**, 1485.
36. A. R. J. V. Vossen, K. R. van Straalen, S. M. A. Swagemakers, J. E. M. M. de Klein, A. P. Stubbs, D. J. Venter, H. H. van der Zee, P. J. van der Spek, E. P. Prens, *J. Eur. Acad. Dermatol. Venereol.* 2020, [online ahead of print].

37. R. Higgins, A. Pink, R. Hunger, N. Yawalkar, A. A. Navarini, *Front. Med.* 2017, **4**, 16.
38. J. W. Frew, K. Navrazhina, *Br. J. Dermatol.* 2020, **182**, 1042.
39. E. J. Giamarellos-Bourboulis, M. Platzter, I. Karagiannidis, T. Kanni, G. Nikolakis, J. Ulrich, M. Bellutti, H. Gollnick, M. Bauer, C. C. Zouboulis, K. Huse, *J. Invest. Dermatol.* 2016, **136**, 1592.
40. M. Coates, P. Mariottoni, D. L. Corcoran, H. F. Kirshner, T. Jaleel, D. A. Brown, S. R. Brooks, J. Murray, M. I. Morasso, A. S. MacLeod, *PLoS. One* 2019, **14**, e0216249.
41. L. K. Hoffman, L. E. Tomalin, G. Schultz, M. D. Howell, N. Anandasabapathy, A. Alavi, M. Suárez-Fariñas, M. A. Lowes, *PLoS. One* 2018, **13**, e0203672.
42. J. L. Blok, K. Li, C. Brodmerkel, M. F. Jonkman, B. Horváth, *Br. J. Dermatol.* 2016, **174**, 1392.
43. V. K. Shanmugam, D. Jones, S. McNish, M. L. Bendall, K. A. Crandall, *Clin. Exp. Dermatol.* 2019, **44**, 882.
44. W. Alwan, F. O. Nestle, *Clin. Exp. Rheumatol.* 2015, **33**, S2.
45. M. Hofmann-Apitius, M. E. Alarcón-Riquelme, C. Chamberlain, D. McHale, *Nat. Rev. Drug Discov.* 2015, **14**, 75.
46. S. Lantuejoul, M. Sound-Tsao, W. A. Cooper, N. Girard, F. R. Hirsch, A. C. Roden, F. Lopez-Rios, D. Jain, T.-Y. Chou, N. Motoi, K. M. Kerr, Y. Yatabe, E. Brambilla, J. Longshore, M. Papotti, L. M. Sholl, E. Thunnissen, N. Rekhtman, A. Borczuk, L. Bubendorf, Y. Minami, M. B. Beasley, J. Botling, G. Chen, J.-H. Chung, S. Dacic, D. Hwang, D. Lin, A. Moreira, A. G. Nicholson, M. Noguchi, G. Pelosi, C. Poleri, W. Travis, A. Yoshida, J. B. Daigneault, I. I. Wistuba, M. Mino-Kenudson, *J. Thorac. Oncol.* 2020, **15**, 499.
47. A. Garg, J. S. Kirby, J. Lavian, G. Lin, A. Strunk, *JAMA. Dermatology* 2017, **153**, 760.
48. A. Garg, S. Wertenteil, R. Baltz, A. Strunk, N. Finelt, *J. Invest. Dermatol.* 2018, **138**, 2152.
49. M. Ianhez, J. V. Schmitt, H. A. Miot, *Int. J. Dermatol.* 2018, **57**, 618.
50. T. Omine, T. Miyagi, K. Hayashi, S. Yamaguchi, K. Takahashi, *J. Dermatol.* 2020, **47**, 855.
51. K. Hayama, H. Fujita, T. Hashimoto, T. Terui, *J. Dermatol.* 2020, **47**, 743.
52. E. Choi, A. R. Cook, N. S. Chandran, *Skin Appendage Disord.* 2018, **4**, 281.
53. E. Choi, N. S. Chandran, *Int. J. Dermatol.* 2019, **58**, e57.
54. M. Yüksel, P. Basım, *J. Cutan. Med. Surg.* 2020, **24**, 55.
55. D. Mintoff, D. L. Camilleri, S. Aquilina, M. J. Boffa, E. Clark, L. Scerri, *Clin. Exp. Dermatol.* 2020, **45**, 758.

56. A. Mebazaa, R. B. Hadid, R. C. Rouhou, S. Trojjet, D. El Euch, M. Mokni, M. Zitouna, A. Ben Osman, *Acta Dermatovenerol. Alp. Pannonica Adriat.* 2009, **18**, 165.
57. P. C. Morss, M. L. Porter, K. T. Savage, M. R. Santillan, N. Giannotti, A. B. Kimball, *J. Eur. Acad. Dermatol. Venereol.* 2020, **34**, e139.
58. Y. S. Soliman, L. K. Hoffman, A. K. Guzman, Z. S. Patel, M. A. Lowes, S. R. Cohen, *J. Cutan. Med. Surg.* 2019, **23**, 334.
59. J. R. Ingram, *Dermatol. Clin.* 2016, **34**, 23.
60. K. N. Price, L. Hsiao, V. Y. Shi, *Dermatology* 2019, [online ahead of print].
61. I. Kurokawa, N. Hayashi, *J. Dermatol.* 2015, **42**, 747.
62. F. Canoui-Poitrine, A. Le Thuaut, J. E. Revuz, C. Viallette, G. Gabison, F. Poli, F. Pouget, P. Wolkenstein, S. Bastuji-Garin, *J. Invest. Dermatol.* 2013, **133**, 1506.
63. A. Martorell, G. Giovanardi, P. Gomez-Palencia, V. Sanz-Motilva, *J. Eur. Acad. Dermatol. Venereol.* 2020, **34**, 1309.
64. H. H. van der Zee, G. B. E. Jemec, *J. Am. Acad. Dermatol.* 2015, **73**(suppl 1), S23.
65. J. M. Frew, J. E. Hawkes, M. Sullivan-Whalen, P. Gilleaudeau, J. G. Krueger, *Br. J. Dermatol.* 2019, **181**, 566.
66. K. R. van Straalen, H. H. van der Zee, *Br. J. Dermatol.* 2019; **181**, 224.
67. J. R. Ingram, V. Piguet, *J. Invest. Dermatol.* 2013, **133**, 1453.
68. M. Daxhelet, M. Suppa, F. Benhadou, V. Djamei, T. Tzellos, G. Ingvarsson, J. Boer, A. Martorell, J. R. Ingram, N. Desai, A. Nassif, J. Revuz, C. Hotz, V. Bettoli, I. E. Deckers, G. B. E. Jemec, E. Prens, C. C. Zouboulis, V. Del Marmol, *J. Eur. Acad. Dermatol. Venereol.* 2016, **30**, 1424.
69. H. Guet-Revillet, H. Coignard-Biehler, J. P. Jais, G. Quesne, E. Frapy, S. Poirée, A. S. Le Guern, A. Le Flèche-Matéos, A. Hovnanian, P. H. Consigny, O. Lortholary, X. Nassif, A. Nassif, O. Join-Lambert, *Emerg. Infect. Dis.* 2014, **20**, 1990.
70. H. C. Ring, V. Sigsgaard J. Thorsen, K. Fursted, S. Fabricius, D. M. Saunte, G. B. Jemec, *J. Eur. Acad. Dermatol. Venereol.* 2019, **33**, 1775.
71. O. Join-Lambert, H. Coignard, J. P. Jais, H. Guet-Revillet, S. Poirée, S. Fraitag, V. Jullien, F. Ribadeau-Dumas, J. Thèze, A. S. Le Guern, S. Behillil, A. Leflèche, P. Berche, P. H. Consigny, O. Lortholary, X. Nassif, A. Nassif, *Dermatology* 2011, **222**, 49.
72. M. Delage, J. P. Jais, T. Lam, H. Guet-Revillet, M. N. Ungeheuer, P. H. Consigny, A. Nassif, O. Join-Lambert, *J. Am. Acad. Dermatol.* 2020, [online ahead of print].

73. O. Join-Lambert, H. Coignard-Biehler, J. P. Jais, M. Delage, H. Guet-Revillet, S. Poirée, S. Duchatelet, V. Jullien, A. Hovnanian, O. Lortholary, X. Nassif, A. Nassif, *J. Antimicrob. Chemother.* 2016, **71**, 513.
74. H. C. Ring, L. Bay K. Kallenbach, I. M. Miller, E. Prens, D. M. Saunte, T. Bjarnsholt, G. B. E. Jemec, *Acta Derm. Venereol.* 2017, **97**, 208.
75. H. C. Ring, L. Bay, M. Nilsson, K. Kallenbach, I. M. Miller, D. M. Saunte, T. Bjarnsholt, T. Tolker-Nielsen, G. B. E. Jemec, *Br. J. Dermatol.* 2017, **176**, 993.
76. É. Riverain-Gillet, H. Guet-Revillet, J. P. Jais, M. N. Ungeheuer, S. Duchatelet, M. Delage, T. Lam, A. Hovnanian, A. Nassif, O. Join-Lambert, *J. Invest. Dermatol.* 2020, [online ahead of print].
77. A. M. Schneider, L. C. Cook, X. Zhan, K. Banerjee, Z. Cong, Y. Imamura-Kawasawa, S. L. Gettle, A. L. Longenecker, J. S. Kirby, A. M. Nelson, *J. Invest. Dermatol.* 2020, **140**, 716.
78. L. H. Perez, M. Butler, T. Creasey, J. Dzink-Fox, J. Gounarides, S. Petit, A. Ropenga, N. Ryder, K. Smith, P. Smith, S. J. Parkinson, *PLoS. One* 2010, **5**, e10915.
79. M. H. Ghas, M. J. Hyde, L. E. Tomalin, B. P. Morgan, A. Alavi, M. A. Lowes, V. Piguet, *J. Invest. Dermatol.* 2020, **140**, 531.
80. D. Grand, K. Navrazhina, J. W. Frew, *Exp. Dermatol.* 2020, **29**, 86.
81. T. Kanni, O. Zenker, M. Habel, N. Riedemann, E. J. Giamarellos-Bourboulis, *Br. J. Dermatol.* 2018, **179**, 413.
82. E. J. Giamarellos-Bourboulis, M. Argyropoulou, T. Kanni, T. Spyridopoulos, I. Otto, O. Zenker, R. Guo, N. C. Riedemann, *Br. J. Dermatol.* 2020, **183**, 176.
83. C. Marasca, A. Ruggiero, M. C. Annunziata, G. Fabbrocini, M. Megna, *J. Eur. Acad. Dermatol. Venereol.* 2020, **34**, e249.
84. E. J. Giamarellos-Bourboulis, M. G. Netea, N. Rovina, K. Akinosoglou, A. Antoniadou, N. Antonakos, G. Damoraki, T. Gkavogianni, M. E. Adami, P. Katsaounou, M. Ntaganou, M. Kyriakopoulou, G. Dimopoulos, I. Koutsodimitropoulos, D. Velissaris, P. Koufargyris, A. Karageorgos, K. Katrini, V. Lekakis, M. Lupse, A. Kotsaki, G. Renieris, D. Theodoulou, V. Panou, E. Koukaki, N. Koulouris, C. Gogos, A. Koutsoukou, *Cell Host Microbe* 2020, **27**, 992.
85. M. G. Netea, E. J. Giamarellos-Bourboulis, J. Domínguez-Andrés, N. Curtis, R. van Crevel, F. L. van de Veerdonk, M. Bonten, *Cell* 2020, **181**, 969.



86. A. Polycarpou, M. Howard, C. A. Farrar, R. Greenlaw, G. Fanelli, R. Wallis, L. S. Klavinskis, S. Sacks, *EMBO. Mol. Med.* 2020, **12**, e12642.
87. A. Java, A. J. Apicelli, M. K. Liszewski, A. Coler-Reilly, J. P. Atkinson, A. H. Kim, H. S. Kulkarni, *JCI. Insight* 2020, **5**, 140711.
88. T. Gao, M. Hu, X. Zhang, H. Li, L. Zhu, H. Liu, Q. Dong, Z. Zhang, Z. Wang, Y. Hu, Y. Fu, Y. Jin, K. Li, S. Zhao, Y. Xiao, S. Luo, L. Li, L. Zhao, J. Liu, H. Zhao, Y. Liu, W. Yang, J. Peng, X. Chen, P. Li, Y. Liu, Y. Xie, J. Song, L. Zhang, Q. Ma, X. Bian, W. Chen, X. Liu, Q. Mao, C. Cao, medRxiv 2020.03.29.20041962.
89. Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia (PANAMO) NCT04333420. Clinicaltrial.gov
90. C. Marasca, M. C. Annunziata, M. Napolitano, G. Fabbrocini G, *Expert Rev. Clin. Pharmacol.* 2018, **11**, 879
91. C. Marasca, A. Ruggiero, M. Megna, M. C. Annunziata, G. Fabbrocini G, *J. Dermatolog. Treat.* 2020, [online ahead of print].
92. B. Moran, C. M. Sweeney, R. Hughes, A. Malara, S. Kirthi, A.-M. Tobin, B. Kirby, J. M. Fletcher, *J. Invest. Dermatol.* 2017, **137**, 2389.
93. A. S. Byrd, C. Carmona-Rivera, L. J. O'Neil, P. M. Carlucci, C. Cisar, A. Z. Rosenberg, M. L. Kerns, J. A. Caffrey, S. M. Milner, J. M. Sacks, O. Aliu, K. P. Broderick, J. S. Reichner, L. S. Miller, S. Kang, W. H. Robinson, G. A. Okoye, M. J. Kaplan, *Sci. Trans. Med.* 2019, **11**, eaav5908.
94. J. W. Frew, J. E. Hawkes, J. G. Krueger, *F1000Res.* 2018, **7**, 1923.
95. J. Musilova, B. Moran, C. M. Sweeney, A. Malara, A. Zaborowski, R. Hughes, D. C. Winter, J. M. Fletcher, B. Kirby, *J. Invest. Dermatol.* 2020, **140**, 1091.
96. F. Assan, J. Gottlieb, F. Tubach, S. Lebbah, N. Guigue, G. Hickman, E. Pape, M. Madrange, E. Delaporte, B. Sendid, F. Aubin, F. Derouin, S. Bretagne, P. Richette, A. Smahi, E. Sbidian, H. Bachelez, *J. Allergy Clin. Immunol.* 2020, **146**, 452.
97. K. Navrazhina, J. W. Frew, P. Gillaudeau, M. Sullivan-Whalen, S. Garcet, J. G. Krueger JG, *J. Allergy Clin. Immunol.* 2020, [in press].
98. A. S. Byrd, Y. Dina, U. J. Okoh, Q. Q. Quartey, C. Carmona-Rivera, D. W. Williams, M L. Kerns, R. J. Miller, L. Petukhova, H. B. Naik, L. A. Barnes, W. D. Shipman, J. A. Caffrey, J. M. Sacks, S. M. Milner, O. Aliu, K. P. Broderick, D. Kim, H. Liu, C. A. Dillen, R. Ahn, J. W.

- Frew, M. J. Kaplan, S. Kang, L. A. Garza, L. S. Miller, A. Alavi, M. A. Lowes, G. A. Okoye, *Sci. Rep.* 2019, **9**, 12207.
99. J. W. Frew, V. Piguet, *J. Invest. Dermatol.* 2020, **140**, 1323.
100. Q. Q. Quartey, R. J. Miller, B. L. Pinsker, U. J. Okoh, W. D. Shipman, B. A. George, C. C. Nwizu, L. A. Barnes, M. L. Kerns, J. A. Caffrey, O. Aliu, I. D. Brown, F. Succaria, J. P. Maynard, A. S. Herbert, S. Kang, L. S. Miller, G. A. Okoye, A. S. Byrd, *Clin. Exp. Dermatol.* 2020, **45**, 202.
101. E. Pippi, S. Nayar, D. H. Gardner, S. Colafrancesco, C. Smith, F. Barone, *Front. Immunol.* 2018, **8**, 1952.
102. R. Thomi, S. Cazzaniga, S. M. Seyed Jafari, C. Schlapbach, R. E. Hunger, *JAMA. Dermatol.* 2018, **154**, 592.
103. C. W. Wieland, T. Vogl, A. Ordelman, H. G. M. Vloedgraven, L. H. A. Verwoolde, J. M. Rensen, J. Roth, J. Boer, J. Hessels, *Br. J. Dermatol.* 2013, **168**, 1252.
104. N. K. Archer, N. D. Adappa, J. N. Palmer, N. A. Cohen, J. M. Harro, S. K. Lee, L. S. Miller, M. E. Shirliff, *Infect. Immun.* 2016, **84**, 3575.
105. D. M. L. Saunte, G. B. E. Jemec, *JAMA.* 2017, **318**, 2019.
106. G. Kelly, R. Hughes, T. McGarry, M. van den Born, K. Adamzik, R. Fitzgerald, C. Lawlor, A. M. Tobin, C. M. Sweeney, B. Kirby, *Br. J. Dermatol.* 2015, **173**, 1431.
107. E. Prens, I. Deckers, *J. Am. Acad. Dermatol.* 2015, **73**(suppl 1), S8.
108. R. Thomi, M. Kakeda, N. Yawalkar, C. Schlapbach, R. E. Hunger, *J. Eur. Acad. Dermatol. Venereol.* 2017, **31**, 2091.
109. A. Jenei, Z. Dajnoki, B. Medgyesi, K. Gaspar, G. Beke, A. Kinyo, G. Méhes, Z. Hendrik, T. Dinya, D. Töröcsik, C. C. Zouboulis, E. P. Prens, T. Biró, A. Szegedi, A. Kapitány, *J. Invest. Dermatol.* 2019, **139**, 964.
110. I. Karagiannidis, G. Nikolakis, C. C. Zouboulis, *Dermatol. Clin.* 2016, **34**, 45.
111. P. Theut Riis, H. C. Ring, L. Themstrup, G. B. E. Jemec, *Acta Dermatovenerologica Croat.* 2016, **24**, 239.
112. J. H. Barth, A. M. Layton, W. J. Cunliffe, *Br. J. Dermatol.* 1996, **134**, 1057.
113. G. B. E. Jemec, L. J. Margesson, F. W. Danby, *Best Pract. Res. Clin. Obstet. Gynaecol.* 2014, **28**, 1013.
114. A. J. Stellon, M. Wakeling, *Br. Med. J.* 1989, **298**, 28.
115. G. Nikolakis, A. Kyrgidis, C. C. Zouboulis, *Am. J. Clin. Dermatol.* 2019, **20**, 503.

- 116.I. Karagiannidis, G. Nikolakis, R. Sabat, c. C. Zouboulis, *Rev. Endocr. Metab. Disord.* 2016, **17**, 335.
- 117.C. C. Zouboulis, N. Desai, L. Emtestam, R. E. Hunger, D. Ioannides, I. Juhász, J. Lapins, L. Matusiak, E. P. Prens, J. Revuz, S. Schneider-Burrus, J. C. Szepietowski, H. H. van der Zee, G. B. E. Jemec, *J. Eur. Acad. Dermatol. Venereol.* 2015, **29**, 619.
- 118.A.-H. Ravn Jørgensen, J. Aarestrup, J. L. Baker, S. F. Thomsen, *JAMA. Dermatol.* 2020, [online ahead of print].
- 119.C. Gallagher, S. Kirthi, T. Burke, D. O'Shea, A.-M. Tobin, *JAAD. Case Rep.* 2017, **3**, 436.
- 120.L. Jennings, R. Hambly, R. Hughes, B. Moriarty, B. Kirby, *J. Dermatolog. Treat.* 2020, **31**, 261.
- 121.R. Verdolini, N. Clayton, A. Smith, N. Alwash, B. Mannello, *J. Eur. Acad. Dermatol. Venereol.* 2013, **27**, 1101.
- 122.T. Tzellos, C. C. Zouboulis, W. Gulliver, A. D. Cohen, P. Wolkenstein, G. B. E. Jemec, *Br. J. Dermatol.* 2015, **173**, 1142.
- 123.M. A. González-López, J. L. Hernández, M. Lacalle, C. Mata, M. López-Escobar, R. López-Mejías, V. Portilla, P. Fuentesvilla, A. Corrales, M. C. González-Vela, M. A. González-Gay, R. Blanco, *J. Am. Acad. Dermatol.* 2016, **75**, 329.
- 124.A. Egeberg, G. H. Gislason, P. R. Hansen, *JAMA. Dermatol.* 2016, **152**, 429.
- 125.C. B. Kromann, I. E. Deckers, S. Esmann, J. Boer, E. P. Prens, G. B. E. Jemec, *Br. J. Dermatol.* 2014, **171**, 819.
- 126.C. B. Kromann, K. S. Ibler, V. B. Kristiansen, G. B. E. Jemec, *Acta Derm. Venereol.* 2014, **94**, 553.
- 127.A. Malara, R. Hughes, L. Jennings, C. M. Sweeney, M. Lynch, F. Awdeh, I. Timoney, A. M. Tobin, K. Lynam-Loane, L. Tobin, A. Hogan, D. O'Shea, B. Kirby, *Br. J. Dermatol.* 2018, **178**, 792.
- 128.O. Osborn, J. M. Olefsky, *Nat. Med.* 2012, **18**, 363.
- 129.Y. Hu, Y. Zhu, N. Lian, M. Chen, A. Bartke, R. Yuan, *Front. Endocrinol. (Lausanne)* 2019, **10**, 788.
- 130.M. A. González-López, I. Vilanova, G. Ocejó-Viñals, R. Arlegui, I. Navarro, S. Guiral, C. Mata, M. G. Pérez-Paredes, V. Portilla, A. Corrales, M. C. González-Vela, M. A. González-Gay, R. Blanco, J. L. Hernández, *Arch. Dermatol. Res.* 2019, [online ahead of print].
- 131.N. Kloting, M. Bluher, *Rev. Endocr. Metab. Disord.* 2014, **15**, 277.

- 132.I. Mothe-Satney, C. Filloux, H. Amghar, C. Pons, V. Bourlier, J. Galitzky, P. A. Grimaldi, C. C. Féral, A. Bouloumié, E. Van Obberghen, J. G. Neels, *Diabetes* 2012, **61**, 2311.
- 133.A. P. Simopoulos, *Nutrients* 2016, **8**, 128.
- 134.P. Li, D. Y. Oh, G. Bandyopadhyay, W. S. Lagakos, S. Talukdar, O. Osborn, A. Johnson, H. Chung, M. Maris, J. M. Ofrecio, S. Taguchi, M. Lu, J. M. Olefsky, *Nat. Med.* 2015, **21**, 239.
- 135.D. Y. Oh, J. M. Olefsky, *Nat. Rev. Drug Discov.* 2016, **15**, 161.
- 136.C. A. Penno, P. Jäger, C. Laguerre, F. Hasler, A. Hofmann, S. K. Gass, B. Wettstein-Ling, D. J. Schaefer, A. Avrameas, F. Raulf, G. Wiczorek, J. C. U. Lehmann, C. Loesche, L. Roth, T. A. Röhn, *J. Invest. Dermatol.* 2020, [online ahead of print].
- 137.A. König, C. Lehmann, R. Rempel, R. Happel, *Dermatology* 1999, **198**, 261.
- 138.H. Kurzen, I. Wessler, C. J. Kirkpatrick, K. Kawashima, S. A. Grando, *Horm. Metab. Res.* 2007, **39**, 125.
- 139.F. Deilhes, R. M. Rouquet, Y. Gall, C. Aquilina, C. Paul, M. P. Konstantinou, *J. Eur. Acad. Dermatol. Venereol.* 2020, [online ahead of print].
- 140.D. H. Brunzell, A. M. Stafford, C. Dixon, *Curr. Addict. Rep.* 2015, **2**, 33.
- 141.A. I. Chernyavsky, J. Arredondo, L. M. Marubio, S. A. Grando, *J. Cell Sci.* 2004, **117**, 5665.
- 142.H. Kurzen, C. Henrich, D. Booken, N. Poenitz, A. Gratchev, C. D. Klemke, M. Engstner, S. Goerd, N. Maas-Szabowski, *J. Invest. Dermatol.* 2006, **126**, 2458.
- 143.A. Hana, D. Booken, C. Henrich, A. Gratchev, N. Maas-Szabowski, S. Goerd, H. Kurzen, *Life Sci.* 2007, **80**, 2214.
- 144.H. Kurzen, C. Fademrecht, S. Goerd, H. Seltmann, C. C. Zouboulis, A. Gratchev, *Exp. Dermatol.* 2008, **15**, 644.
- 145.C. S. Pavia, A. Pierre, I. Nowakowski, *J. Med. Microbiol.* 2000, **49**, 675.
- 146.C. Schlapbach, N. Yawalkar, R. E. Hunger, *J. Am. Acad. Dermatol.* 2009, **61**, 58.
- 147.F. Petrescu, S. Voican, I. Silosi, *Int. J. Chron. Obstruct. Pulmon. Dis.* 2010, **5**, 217.
- 148.E. Mortaz, P. A. Henricks, A. D. Kraneveld, M. E. Givi, J. Garssen, G. Folkerts, *Biochim. Biophys. Acta* 2011, **1812**, 1104.
- 149.S. Eltom, M. G. Belvisi, C. S. Stevenson, S. A. Maher, E. Dubuis, K. A. Fitzgerald, M. A. Birell, *PLoS. One* 2014, **9**, e112829.
- 150.F. Zhang, M. Y. Li, Y. T. Lan, C. Wang, *Sci. Rep.* 2016, **6**, 21348.
- 151.C. Di Sano, C. D'Anna, M. Ferraro, G. Chiappara, C. Sangiorgi, S. Di Vincenzo, A. Bertani, P. Vitulo, A. Bruno, P. Dino, E. Pace, *Toxicol. Lett.* 2020, **326**, 61.

- 152.A. Kasai, N. Hiramatsu, K. Hayakawa, J. Yao, S. Maeda, M. Kitamura, *Cancer Res.* 2006, **66**, 7143.
- 153.T. Hu, Z. Pan, Q. Yu, X. Mo, N. Song, M. Yan, C. C. Zouboulis, L. Xia, Q. Ju, *Environ. Toxicol. Pharmacol.* 2016, **43**, 54.
- 154.A. A. Panteleyev, D. R. Bickers, *Exp. Dermatol.* 2006, **15**, 705.
- 155.G. B. E. Jemec, *Dermatology* 2011, **222**, 196.
- 156.C. C. Zouboulis, A. Nogueira da Costa, S. Fimmel, K. C. Zouboulis, *J. Eur. Acad. Dermatol. Venereol.* 2020, **34**, 1555.
- 157.C. C. Yu, M. G. Cook, *Br. J. Dermatol.* 1990, **122**, 763.
- 158.G. B. E. Jemec, U. Hansen U, *J. Am. Acad. Dermatol.* 1996, **34**, 994.
- 159.M. von Laffert, P. Helmbold, J. Wohlrab, E. Fiedler, V. Stadie, W. C. Marsch, *Exp. Dermatol.* 2010, **19**, 533.
- 160.J. Boer, E. F. Weltevreden, *Br. J. Dermatol.* 1996, **135**, 721.
- 161.C. Orvain, Y.-L. Lin, F. Jean-Louis, H. Hocini, B. Hersant, Y. Bennasser, N. Ortonne, C. Hotz, P. Wolkenstein, M. Boniotto, P. Tisserand, C. Lefebvre, J.-D. Lelièvre, M. Benkirane, P. Pasero, Y. Lévy, S. Hüe, *J. Clin. Invest.* 2020, **130**, 3777.
- 162.N. Ali, B. Zirak, R. Sanchez Rodriguez, M. L. Pauli, H.-A. Truong, K. Lai, R. Ahn, K. Corbin, M. M. Lowe, T. C. Scharschmidt, K. Taravati, M. R. Tan, R. R. Ricardo-Gonzalez, A. Nosbaum, M. Bertolini, W. Liao, F. O. Nestle, R. Paus, G. Cotsarelis, A. K. Abbas, M. D. Rosenblum, *Cell* 2017, **169**, 1119.
- 163.F. W. Danby, G. B. E. Jemec, W. C. Marsch, M. von Laffert, *Br. J. Dermatol.* 2013, **168**, 1034.
- 164.K. J. McElwee, A. Gilhar, D. J. Tobin, Y. Ramot, J. P. Sundberg, M. Nakamura, M. Bertolini, S. Inui, Y. Tokura, L. E. King Jr, B. Duque-Estrada, A. Tosti, A. Keren, S. Itami, Y. Shoenfeld, A. Zlotogorski, R. Paus, *Exp. Dermatol.* 2013, **22**, 609.
- 165.L. Xing, Z. Dai, A. Jabbari, J. E. Cerise, C. A. Higgins, W. Gong, A. de Jong, S. Harel, G. M. DeStefano, L. Rothman, P. Singh, L. Petukhova, J. Mackay-Wiggan, A. M. Christiano, R. Clynes, *Nat. Med.* 2014, **20**, 1043.
- 166.J. H. Lee, H. S. Kwon, H. M. Jung, G. M. Kim, J. M. Bae, *J. Eur. Acad. Dermatol. Venereol.* 2018, **32**, 1784.
- 167.A. Gilhar, A. Etzionin, R. Paus R, *N. Engl. J. Med.* 2012, **366**, 1515.
- 168.M. Horissian, S. Maczuga, J. S. Kirby, A. M. Nelson, *J. Am. Acad. Dermatol.* 2019, **81**, 1431.

- 169.H. Naasan, A. Affleck, *Clin. Exp. Dermatol.* 2015, **40**, 891.
- 170.J. Gasparic, P. Theut Riis, G. B. E. Jemec, *J. Eur. Acad. Dermatol. Venereol.* 2017, **31**, 1809.
- 171.C. Vinkel, S. F. Thomsen, *Int. J. Dermatol.* 2017, **56**, 811.
- 172.M. Braun-Falco, O. Kovnerystyy, P. Lohse, T. Ruzicka, *J. Am. Acad. Dermatol.* 2012, **66**, 409.
- 173.A. V. Marzano, V. Trevisan, M. Gattorno, I. Ceccherini, C. De Simone, C. Crosti, *JAMA Dermatol.* 2013, **149**, 762.
- 174.V. Bruzzese, *J. Clin. Rheumatol.* 2012, **18**, 413.
- 175.R. Saraceno, G. Babino, A. Chiricozzi, A. Zangrilli, S. Chimenti, *J. Am. Acad. Dermatol.* 2015, **72**, e42.
- 176.M. Cugno, A. Borghi, A. V. Marzano, *Am. J. Clin. Dermatol.* 2017, **18**, 555.
- 177.J. Boer, D. Mihajlovic, *Acta Dermatovenerol. Croat.* 2016, **24**, 303.
- 178.J. Boer, *Dermatology* 2017, **233**, 47.
- 179.K. Sukhdeo, J. Beasley, A. Femia, R. Kim, *Dermatol. Online J.* 2017, **23**, 13030.
- 180.N. A. Veniaminova, M. Grachtchouk, O. J. Doane, J. K. Peterson, D. A. Quigley, M. V. Lull, D. V. Pyrozhenko, R. R. Nair, M. T. Patrick, A. Balmain, A. A. Dlugosz, L. C. Tsoi, S. Y. Wong, *Dev. Cell* 2019, **51**, 326.
- 181.Ł. Matusiak, J. Szczęch, K. Kaaz, E. Lelonek, J. C. Szepietowski, *Acta Derm. Venereol.* 2018, **98**, 191.
- 182.J. M. Fernandez, O. H. Rizvi, K. D. Marr, K. N. Price, A. J. Hendricks, J. L. Hsiao, V. Y. Shi, *Int. J. Dermatol.* 2020, [online ahead of print].
- 183.A. R. J. V. Vossen, A. Schoenmakers, K. R. van Straalen, E. P. Prens, H. H. van der Zee, *Am. J. Clin. Dermatol.* 2017, **18**, 687.
- 184.H. C. Ring, P. Theut Riis, K. Zarchi, I. M. Miller, D. M. Saunte, G. B. E. Jemec, *Clin. Exp. Dermatol.* 2017, **42**, 261.
- 185.A. R. J. V. Vossen, H. H. van der Zee, E. P. Prens, *Front. Immunol.* 2018, **9**, 2965.
- 186.P. Baral, S. Udit, I. M. Chiu, *Nat. Rev. Immunol.* 2019, **19**, 433.
- 187.R.-R. Ji, Z.-Z. Xu, Y.-J. Gao, *Nat. Rev. Drug Discov.* 2014, **13**, 533.
- 188.L. Misery, E. Brenaut, R. Le Garrec R, C. Abasq, S. Genestet, P. Marcorelles, F. Zagnoli, *Nat. Rev. Neurol.* 2014, **10**, 408.
- 189.K. R. van Straalen, *JAMA Dermatol.* 2020; [online ahead of print].

- 190.P. M. Grace, M. R. Hutchinson, S. F. Maier, L. R. Watkins, *Nat. Rev. Immunol.* 2014, **14**, 217.
- 191.A. B. Kimball, M. Sundaram, A. L. Shields, S. Hudgens, M. Okun, C. Foley, A. Ganguli, *J. Am. Acad. Dermatol.* 2018, **79**, 1141.
- 192.C.C. Zouboulis, A. Nogueira da Costa, *J. Invest. Dermatol.*, in press.
- 193.M. H. Ghias, A. D. Johnston, A. J. Kutner, R. G. Micheletti, H. D. Hosgood, S. R. Cohen, *J. Am. Acad. Dermatol.* 2020, **82**, 1094.
- 194.C. C. Zouboulis, H. Hansen, R. D. Caposiena Caro, G. Damiani, I. Delorme, J. C. Pascual, Z. Reguiari, A. Trigoni, E. Vilarrasa, F. Alfageme Roldán, *Dermatology* 2020, **236**, 25.
- 195.C. C. Zouboulis, V. del Marmol, U. Mrowietz, E. Prens, T. Tzellos, G. B. E. Jemec, *Dermatology* 2015, **231**, 184.
- 196.A. B. Kimball, J. M. Sobell, C. C. Zouboulis, Y. Gu, D. A. Williams, M. Sundaram, H. D. Teixeira, G. B. E. Jemec, *J. Eur. Acad. Dermatol. Venereol.* 2016, **30**, 989.
- 197.C. C. Zouboulis, *Br. J. Dermatol.* 2019, **181**, 244.
- 198.C. C. Zouboulis, A. Nogueira da Costa, *Dermatology* 2019, **235**, 51.
- 199.C. C. Zouboulis, A. Nogueira da Costa, G. B. E. Jemec, D. Trebing, *Dermatology* 2019, **235**, 144.
- 200.X. Wortsman, *J. Eur. Acad. Dermatol. Venereol.* 2020, [online ahead of print].

**Table 1. Association of drug repurposing studies with clinical experience in HS**

| Agent          | Mechanism of Action           | Targets                          | Strength of existing clinical data supporting effect |
|----------------|-------------------------------|----------------------------------|--|
| Apremilast     | Phosphodiesterase-4 inhibitor | IFN $\gamma$ + TNF/TNF- $\alpha$ | ++   |
| Gentamycin     | Antibiotic                    | GAS6 + IL17/IL17A                |  |
| Spironolactone | Antiandrogen                  | AR + TNF/TNF- $\alpha$           | ++   |
| Thalidomide    | Immune modulator              | HGF + TNF/TNF- $\alpha$          |  |
| Prednisone     | Immune suppressor             | NF $\kappa$ B                    | +  |



## LEGENDS TO THE FIGURES

**Fig. 1. Genetic and environmental triggers have been implicated in the pathogenesis of hidradenitis suppurative (HS).** These result in skin microbiome alterations and a cascade of inflammatory, immune-mediated responses that lead to upregulated innate immunity.

Associations with HS have been reported with cardio-metabolic diseases as well as autoimmune rheumatic diseases. Cardiometabolic diseases include diabetes mellitus/insulin resistance, obesity, dyslipidaemia, hypertension. Autoimmune diseases in the rheumatic spectrum include Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis (SAPHO) syndrome, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus. The overall outcome of uncontrolled autoinflammation/autoimmunity is an altered host-microbiome crosstalk. DC, dendritic cell; IL, interleukin; LTB<sub>4</sub>, leukotriene B<sub>4</sub>; MΦ, macrophage; PMN, polymorphonuclear cell; Th, T-helper cell; TNF, tumor necrosis factor. S100A7/A8/A9 & LL-37 represent antimicrobial peptides.

**Fig. 2. Proposed key cells and mediators in the evolution of hidradenitis suppurativa (HS) and pathogenesis-based target therapies.** HS is an inflammatory skin disease with a characteristic clinical presentation of recurrent or chronic painful, itching or suppurating lesions in the apocrine sweat gland-bearing regions of the body. Key processes during disease involve epidermal changes within the hair follicle infundibulum which culminate in follicular clogging and subsequent rupture and release of follicular content into the surrounding tissue triggering an inflammatory response. While the underlying inflammatory process are not fully understood, a multitude of immune cells infiltrate skin lesions and lead to tissue destruction of pilosebaceous and sweat gland units. Likely as a response to healing from the inflammatory process, tunneling and tissue scarring can occur, worsening the clinical disease course. While early lesions have been reported to harbor normal bacterial flora for the skin region, dysbiosis and secondary infections with biofilm formation have been reported. Current non-biologic based therapies as well as targeted biologic therapies that are proposed or have been FDA-approved (adalimumab) or have been approved for clinical trials are shown. IFN, interferon; IL, interleukin; JAK, Janus kinase; LTB<sub>4</sub>, leukotriene B<sub>4</sub>; Th, T-helper cell; TNF, tumor necrosis factor. \* highlights the only FDA-approved biologic for hidradenitis suppurativa.

**Fig. 3. A new vision of hidradenitis suppurativa including microbiology in the whole picture.**

The concept makes HS to appear as a host-microbiome syndrome, with different microbiologic phenotypes, which happen to correlate with severity, evolution mode and therapeutic strategies, that have to be different according to microbiology and severity. The role of biofilms, recently


unraveled, persisting in scars and waking up to produce flares in scars only, also justifies the necessary surgical treatment and sounds important to be mentioned in the chronic inflammatory loop.




**Fig. 4. Comparison of observed cellular tissue infiltrates in (A) Normal skin; (B) Hidradenitis suppurativa (HS) Non-Lesional Skin; (C) HS Mild Disease; (D) HS with Tunnels and (E) HS Severe Disease.** Whilst little mechanistic evidence exists to support the linear progression of this model, it is assumed that mechanisms exist to link the individual observed conditions in HS Tissue although this needs further experimental exploration and confirmation. HS, hidradenitis suppurativa, Th, T-helper cell

**Fig. 5. Metabolic factors promoting the development of hidradenitis suppurativa.** BMI, body mass index; HS, hidradenitis suppurativa

**Fig. 6. The possible actions of cigarette smoking in hidradenitis suppurativa.** Ahr, aryl hydrocarbon receptor; nAChRs, nicotinic acetylcholine receptors

Accepted Article







**Informing Future Personalized Therapies of HS**


- Targeted therapy against
- TNF- $\alpha$  Adalimumab\*  
Infliximab
  - IL-12/23 (p40) Ustekinumab
  - IL23(p19) Guselkumab  
Risankizumab  
Secukinumab
  - IL17A Brodalumab
  - IL17R Bimekizumab
  - IL17A/F Anakinra
  - IL-1R Bermekimab
  - IL-1 $\alpha$
  - LTB4
  - Complement pathway
  - JAK pathway

- Antibiotics
- Antiseptics
- Hormonal Treatment
- Wound Management
- Pain Killers
- Intralesional Corticosteroids






exd\_14214\_f4.jpeg







Cigarette smoke



Hidradenitis suppurativa